<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Antioxid Redox Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Antioxid. Redox Signal</journal-id>
<journal-id journal-id-type="publisher-id">ars</journal-id>
<journal-title-group>
<journal-title>Antioxidants &amp; Redox Signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1523-0864</issn>
<issn pub-type="epub">1557-7716</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc.</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26415143</article-id>
<article-id pub-id-type="pmc">4657513</article-id>
<article-id pub-id-type="publisher-id">10.1089/ars.2015.6317</article-id>
<article-id pub-id-type="doi">10.1089/ars.2015.6317</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Forum Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Relevance of Biomarkers of Oxidative Stress</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Frijhoff</surname>
<given-names>Jeroen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winyard</surname>
<given-names>Paul G.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarkovic</surname>
<given-names>Neven</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davies</surname>
<given-names>Sean S.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4,</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stocker</surname>
<given-names>Roland</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6,</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knight</surname>
<given-names>Annie R.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Emma Louise</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oettrich</surname>
<given-names>Jeannette</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruskovska</surname>
<given-names>Tatjana</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gasparovic</surname>
<given-names>Ana Cipak</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9,</sup>
</xref>
<xref ref-type="aff" rid="aff10">
<sup>10,</sup>
</xref>
<xref ref-type="aff" rid="aff11">
<sup>11,</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weber</surname>
<given-names>Daniela</given-names>
</name>
<xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Poulsen</surname>
<given-names>Henrik Enghusen</given-names>
</name>
<xref ref-type="aff" rid="aff14">
<sup>14,</sup>
</xref>
<xref ref-type="aff" rid="aff15">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grune</surname>
<given-names>Tilman</given-names>
</name>
<xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmidt</surname>
<given-names>Harald H.H.W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ghezzi</surname>
<given-names>Pietro</given-names>
</name>
<xref ref-type="aff" rid="aff16">
<sup>16</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Faculty of Health, Medicine and Life Sciences, Cardiovascular Research Institute Maastricht (CARIM), <institution>Maastricht University</institution>, Maastricht, <country>the Netherlands</country>.</aff>
<aff id="aff2"><label><sup>2</sup></label><institution>University of Exeter Medical School</institution>, Exeter, <country>United Kingdom</country>.</aff>
<aff id="aff3"><label><sup>3</sup></label>LabOS, <institution>Rudjer Boskovic Institute</institution>, Zagreb, <country>Croatia</country>.</aff>
<aff id="aff4"><label><sup>4</sup></label>Department of Medicine, <institution>Vanderbilt University</institution>, Nashville, Tennessee.</aff>
<aff id="aff5"><label><sup>5</sup></label>Division of Clinical Pharmacology, Department of Pharmacology, <institution>Vanderbilt University</institution>, Nashville, Tennessee.</aff>
<aff id="aff6"><label><sup>6</sup></label>Vascular Biology Division, <institution>Victor Chang Cardiac Research Institute</institution>, Darlinghurst, New South Wales, <country>Australia</country>.</aff>
<aff id="aff7"><label><sup>7</sup></label>School of Medical Sciences, <institution>University of New South Wales</institution>, Sydney, New South Wales, <country>Australia</country>.</aff>
<aff id="aff8"><label><sup>8</sup></label>Faculty of Medical Sciences, <institution>Goce Delcev University</institution>, Stip, <country>Macedonia</country>.</aff>
<aff id="aff9"><label><sup>9</sup></label><institution>Centro de Investigación Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</institution>, ISCIII, Madrid, <country>Spain</country>.</aff>
<aff id="aff10"><label><sup>10</sup></label><institution>Instituto de Investigaciones Biomedicas “Alberto Sols” UAM-CSIC</institution>, Madrid, <country>Spain</country>.</aff>
<aff id="aff11"><label><sup>11</sup></label><institution>Instituto de Investigacion Sanitaria La Paz (IdiPaz)</institution>, Madrid, <country>Spain</country>.</aff>
<aff id="aff12"><label><sup>12</sup></label>Department of Biochemistry, Faculty of Medicine, <institution>Autonomous University of Madrid</institution>, Madrid, <country>Spain</country>.</aff>
<aff id="aff13"><label><sup>13</sup></label>Department of Molecular Toxicology, <institution>German Institute of Human Nutrition (DIfE)</institution>, Nuthetal, <country>Germany</country>.</aff>
<aff id="aff14"><label><sup>14</sup></label>Faculty of Health Science, <institution>University of Copenhagen</institution>, Copenhagen, <country>Denmark</country>.</aff>
<aff id="aff15"><label><sup>15</sup></label><institution>Bispebjerg-Frederiksberg Hospital</institution>, Copenhagen, <country>Denmark</country>.</aff>
<aff id="aff16"><label><sup>16</sup></label><institution>Brighton and Sussex Medical School</institution>, Brighton, <country>United Kingdom</country>.</aff>
</contrib-group>
<author-notes>
<corresp>
<addr-line>Address correspondence to:</addr-line>
<addr-line>
<italic>Prof. Pietro Ghezzi</italic>
</addr-line>
<institution>
<italic>Brighton &amp; Sussex Medical School</italic>
</institution>
<addr-line>
<italic>Falmer</italic>
</addr-line>
<addr-line>
<italic>Brighton</italic>
</addr-line>
<country>United Kingdom</country>
<break></break>
<italic>E-mail:</italic>
<email xlink:href="mailto:p.ghezzi@bsms.ac.uk">p.ghezzi@bsms.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>10</day>
<month>11</month>
<year>2015</year>
<!--string-date: November 10, 2015-->
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>11</month>
<year>2015</year>
<!--string-date: November 10, 2015-->
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
<volume>23</volume>
<issue>14</issue>
<fpage>1144</fpage>
<lpage>1170</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>3</month>
<year>2015</year>
<!--string-date: Date of first submission to ARS Central, March 19, 2015-->
</date>
<date date-type="rev-recd">
<day>25</day>
<month>8</month>
<year>2015</year>
<!--string-date: date of final revised submission, August 25, 2015-->
</date>
<date date-type="accepted">
<day>08</day>
<month>9</month>
<year>2015</year>
<!--string-date: date of acceptance, September 8, 2015-->
</date>
</history>
<permissions>
<copyright-statement>© Jeroen Frijhoff et al. 2015; Published by Mary Ann Liebert, Inc.</copyright-statement>
<copyright-year>2015</copyright-year>
<license license-type="open-access">
<license-p>This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="ars.2015.6317.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p><bold><italic>Significance:</italic></bold> Oxidative stress is considered to be an important component of various diseases. A vast number of methods have been developed and used in virtually all diseases to measure the extent and nature of oxidative stress, ranging from oxidation of DNA to proteins, lipids, and free amino acids. <bold><italic>Recent Advances:</italic></bold> An increased understanding of the biology behind diseases and redox biology has led to more specific and sensitive tools to measure oxidative stress markers, which are very diverse and sometimes very low in abundance. <bold><italic>Critical Issues:</italic></bold> The literature is very heterogeneous. It is often difficult to draw general conclusions on the significance of oxidative stress biomarkers, as only in a limited proportion of diseases have a range of different biomarkers been used, and different biomarkers have been used to study different diseases. In addition, biomarkers are often measured using nonspecific methods, while specific methodologies are often too sophisticated or laborious for routine clinical use. <bold><italic>Future Directions:</italic></bold> Several markers of oxidative stress still represent a viable biomarker opportunity for clinical use. However, positive findings with currently used biomarkers still need to be validated in larger sample sizes and compared with current clinical standards to establish them as clinical diagnostics. It is important to realize that oxidative stress is a nuanced phenomenon that is difficult to characterize, and one biomarker is not necessarily better than others. The vast diversity in oxidative stress between diseases and conditions has to be taken into account when selecting the most appropriate biomarker. <italic>Antioxid. Redox Signal.</italic> 23, 1144–1170.</p>
</abstract>
<counts>
<fig-count count="10"></fig-count>
<table-count count="7"></table-count>
<equation-count count="8"></equation-count>
<ref-count count="202"></ref-count>
<page-count count="27"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s001" sec-type="intro">
<title>Introduction</title>
<p>R<sc>edox signaling operates</sc> through discrete, reversible, and site-specific modifications of certain proteins (<xref ref-type="bibr" rid="B184">184</xref>). Reversible modifications of cysteine residues include S-nitrosylation/S-nitrosation, sulfenylation, disulfide bonds, and S-glutathionylation (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B87">87</xref>). These redox signaling-induced changes, performed by reactive oxygen and nitrogen species (ROS and RNS), target protein activities within complex networks of kinases, phosphatases, ion channels, and apoptotic cascades and can cause changes in transcriptional activity (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B83">83</xref>). Oxidative stress, characterized by an imbalance between oxidants and antioxidants in favor of oxidants, leads to disruption of redox signaling and physiological function (<xref ref-type="bibr" rid="B157">157</xref>, <xref ref-type="bibr" rid="B158">158</xref>). Oxidative stress might also lead to irreversible chemical modifications (<xref ref-type="bibr" rid="B152">152</xref>, <xref ref-type="bibr" rid="B164">164</xref>). One of the weaknesses of the underpinning science is the lack of validated oxidative stress biomarkers. Analytical issues surrounding the validation of oxidative stress biomarkers have received substantial attention recently (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B100">100</xref>). However, there remains increasing interest in exploring their potential clinical applications. While the current review will touch upon analytical issues, its focus will be on synthesizing the status—and future potential—of oxidative stress biomarkers as clinical diagnostics from available literature.</p>
<p>The World Health Organization has defined a biomarker as any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease (<xref ref-type="bibr" rid="B192">192</xref>). Markers of oxidative stress often fulfill the first part of the criteria (<italic>i.e.</italic>, they can be measured) and many studies suggest oxidative stress can influence the disease, but to be a <italic>clinically relevant</italic> biomarker, some additional issues must also be addressed. In summary, a clinically useful biomarker must be able to meet one of the following criteria: (i) show specificity for a certain disease (diagnostic), (ii) have prognostic value, and (iii) correlate with disease activity. This then allows treatment efficacy to be assessed. To be clinically useful, a biomarker must also be reasonably stable, present in an easily accessible tissue, and cost-effective to measure reproducibly on a large scale.</p>
<p>An increasing number of studies are published on markers of oxidative stress in a whole range of human diseases (<xref ref-type="fig" rid="f1">Fig. 1</xref>). While a plethora of markers and methods are used, many of these do not correlate well with each other, do not reflect a state of oxidative stress, or are not specific. In this study, we critically review the current state of oxidative stress biomarkers that are used to assess the redox state of the body or specific tissues and cells in health and disease, with a focus on those that can be realistically applied to the clinic (<xref ref-type="fig" rid="f2">Fig. 2</xref>). This approach excludes by definition several commonly used preclinical and <italic>in vitro</italic> methods. Visualization of biomarkers measured in various diseases by cluster analysis (<xref ref-type="fig" rid="f3">Fig. 3</xref>) shows that the majority of studies have used ROS-induced modifications as markers of oxidative stress, which will be discussed first. We then focus on biomarkers assessing two important components whose deregulation can result in oxidative stress, ROS generation, and antioxidant defense. We conclude with two functional markers that are downstream of oxidative stress. From a clinical perspective, what matters is which marker is predictive with respect to risk and therapeutic outcome.</p>
<fig fig-type="figure" id="f1" orientation="portrait" position="float">
<label>
<bold>FIG. 1.</bold>
</label>
<caption>
<p><bold>Publications on oxidative stress biomarkers in different diseases.</bold> Searches were performed using oxidative stress biomarkers patients and the specific disease MeSH term using Web of Science. <bold>(A)</bold> Indicates the number of hits of all diseases combined per 10,000, normalized to a search with patients and the diseases in question. <bold>(B)</bold> Shows the number of hits per disease, which is proportional to the <italic>circle</italic> size, for the years 2005–2015.</p>
</caption>
<graphic xlink:href="fig-1"></graphic>
</fig>
<fig fig-type="figure" id="f2" orientation="portrait" position="float">
<label>
<bold>FIG. 2.</bold>
</label>
<caption>
<p><bold>Redox pathways associated with putative biomarkers of oxidative stress.</bold> The processes that lead to oxidative modifications of proteins, lipids, and nucleotides are highly complex. Enzymes, such as XO, NOX, and NOS, can produce ROS and RNS. These ROS can furthermore serve as substrates for other enzymes to generate additional types of ROS, such as the generation of HOCl from H<sub>2</sub>O<sub>2</sub> by MPO. Cellular systems and enzymes, including the GSH and thioredoxin system, together with peroxiredoxins (T/Prx), counterbalance the production of ROS. In addition, increased levels of ROS activate Nrf2 to transcribe genes that are involved in counteracting these ROS. Oxidative stress affects cGMP signaling through its effects on nitric oxide (<sup><bold>•</bold></sup>NO) production, scavenging, and on the <sup><bold>•</bold></sup>NO receptor sGC. cGMP, cyclic guanosine monophosphate; GSH, glutathione; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; HOCl, hypochlorous acid; MPO, myeloperoxidase; NOS, nitric oxide synthase; NOX, NADPH oxidase; RNS, reactive nitrogen species; ROS, reactive oxygen species; sGC, soluble guanylate cyclase; XO, xanthine oxidase.</p>
</caption>
<graphic xlink:href="fig-2"></graphic>
</fig>
<fig fig-type="figure" id="f3" orientation="portrait" position="float">
<label>
<bold>FIG. 3.</bold>
</label>
<caption>
<p><bold>Cluster analysis of ROS biomarkers in disease.</bold> Different diseases were clustered according to described ROS biomarkers in Refs. (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B181">181</xref>) and studies described in this review. Some disease conditions cluster as might be expected, such as ischemia/reperfusion and heart failure, and amyotrophic lateral sclerosis and multiple sclerosis. A comprehensive analysis of ROS markers and pattern analysis in diseases might uncover common disease mechanisms or new measures of disease progression or treatment outcome. Cluster analysis was performed using Genesis software (<uri xlink:href="http://genome.tugraz.at/genesisclient/genesisclient_description.shtml" xlink:type="simple">https://genome.tugraz.at/genesisclient/genesisclient_description.shtml</uri>) as described in Mengozzi <italic>et al.</italic> (<xref ref-type="bibr" rid="B111">111</xref>).</p>
</caption>
<graphic xlink:href="fig-3"></graphic>
</fig>
</sec>
<sec id="s002">
<title>ROS-Induced Modifications</title>
<p>This category includes biomarkers measuring evidence of direct chemical impact of ROS in biological systems. One of the ROS subsets is also described as RNS, for example, <sup><bold>•</bold></sup>NO and ONOO<sup>−</sup>. Besides causing post-translational modifications of proteins, these species may also cause nitrative stress and RNS-induced modifications, such as tyrosine nitration.</p>
<sec id="s003">
<title>Protein carbonyls and advanced glycation end products</title>
<p>Protein carbonyls are formed through oxidative cleavage of protein backbones. Oxidative deamination of lysine and glutamic acid also results in protein carbonyls (<xref ref-type="bibr" rid="B34">34</xref>). Since carbonyls can arise from different mechanisms, their concentration is commonly higher than that of other biomarkers (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>Carbonyl groups may also be introduced by binding of aldehydic lipid oxidation products to lysine, cysteine, and histidine residues—a reaction termed Michael addition—resulting in advanced lipoxidation end products. Reactions between lysine and arginine residues and carbohydrates—a reaction called glycoxidation—result in advanced glycation end products (AGEs).</p>
<p>AGEs are a group of heterogeneous molecules that arise from the nonenzymatic reaction of reducing sugars with amino groups of lipids, DNA, and especially long-lived proteins. This process occurs during normal metabolism, but is even more pronounced under hyperglycemic, hyperlipidemic, and oxidative stress conditions.</p>
<p>The glycation reaction can be accompanied by an oxidation leading to glycoxidation products. Carboxymethyl valine and pentosidine are among the most prominent AGEs resulting from glycoxidation. Glyoxal, generated from metal-catalyzed oxidation of polyunsaturated fatty acids (PUFAs), forms adducts with lysine (resulting in carboxymethyl lysine [CML]), an advanced lipoxidation product (<xref ref-type="bibr" rid="B55">55</xref>). About 90% of CML and pentosidine in blood are bound to proteins (<xref ref-type="bibr" rid="B116">116</xref>). Due to their relationship to sugars, AGEs have been linked to diabetes mellitus and other diseases, such as obesity (<xref ref-type="bibr" rid="B20">20</xref>), atherosclerosis, renal failure (<xref ref-type="bibr" rid="B193">193</xref>), and Alzheimer's disease (<xref ref-type="bibr" rid="B172">172</xref>). Due to the different possible formation mechanisms and heterogeneity, numerous glycation products exist, of which only some have been characterized so far.</p>
<p>Protein carbonyls (<italic>i.e.</italic>, having aldehyde and ketone moieties) are usually detected after derivatization with 2,4-dinitrophenylhydrazine (DNP). The resulting carbonyl-2,4-dinitrophenylhydrazine adduct (<xref ref-type="bibr" rid="B101">101</xref>) can be detected spectrophotometrically or by specific anti-DNP antibodies with ELISA (<xref ref-type="bibr" rid="B24">24</xref>), Western blot (<xref ref-type="bibr" rid="B91">91</xref>), immunohisto- and cytochemistry, or by high-performance liquid chromatography (HPLC). The results of the ELISA correlate well with the colorimetric assay (<xref ref-type="bibr" rid="B24">24</xref>), whereby the ELISA is more convenient to analyze a larger number of samples within one run and requires significantly less sample volume. Concerning clinical settings, the only methods that seem to be applicable are ELISA (kits are available) and HPLC as they enable high throughput, involve internal/external standards, and comparison of samples under constant conditions.</p>
<p>A number of methods have been reported to measure AGEs based on the use of antibodies for immunohistochemistry, immunoblot, and commercial ELISA, as well as special AGE readers that utilize the autofluorescence properties of AGEs in human skin to assess AGE concentrations. Spectrofluorometry can be applied to diluted plasma or serum samples and a fructosamine assay to detect ketoamines (<xref ref-type="bibr" rid="B9">9</xref>). HPLC allows the identification and measurement of specific AGEs such as pentosidine (<xref ref-type="bibr" rid="B169">169</xref>) and CML (<xref ref-type="bibr" rid="B52">52</xref>). Creatinine glycation products can be measured with stable isotope dilution analysis and liquid chromatography (LC)-MS/MS (<xref ref-type="bibr" rid="B97">97</xref>). Due to the structural heterogeneity of AGEs, there is no method that can be especially recommended for measuring specific AGEs in a clinical setting. Noninvasive spectrographic autofluorescence readers can be applied in a clinical setting; however, this should be standardized in terms of using the average of three readings, the same body region, avoiding surrounding light and skin areas with tattoos. Elevated skin autofluorescence has been demonstrated in diabetes, kidney disease, and in patients with arterial stiffness.</p>
<p>In humans, elevated protein carbonyl levels have been reported in numerous conditions, including aging (<xref ref-type="bibr" rid="B61">61</xref>), neurodegenerative diseases (<xref ref-type="bibr" rid="B62">62</xref>), obesity, diabetes mellitus, age-related macular degeneration (<xref ref-type="bibr" rid="B174">174</xref>), human immunodeficiency virus (HIV), anemia, sickle cell disease, newborn bronchopulmonary dysplasia, and hepatocellular carcinoma (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label><sc>Table</sc> 1.</label>
<caption>
<p>
<sc>Selected Clinical Studies of Protein Carbonyl Levels in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease/Condition</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Observation</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf1">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">HIV-associated cognitive impairment</td>
<td align="left">Cerebrospinal fluid</td>
<td align="left">Commercial Oxyblot kit</td>
<td align="left">No significant differences in PC between treatment and placebo after selegiline transdermal system <italic>versus</italic> placebo.</td>
<td align="center">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
<tr>
<td align="left">Chronic heart failure, secondary to ischemic or idiopathic cardiomyopathy</td>
<td align="left">Plasma</td>
<td align="left">Spectrophotometry</td>
<td align="left">Significantly decreased PC after treatment with darbepoetin alfa (placebo: no effect).</td>
<td align="center">(<xref ref-type="bibr" rid="B75">75</xref>)</td>
</tr>
<tr>
<td align="left">Sickle cell disease</td>
<td align="left">Plasma</td>
<td align="left">Spectrophotometry</td>
<td align="left">α-Lipoic acid treatment in healthy subjects reduced PC (<italic>P</italic> &lt; 0.05), no effect in sickle cell disease.</td>
<td align="center">(<xref ref-type="bibr" rid="B64">64</xref>)</td>
</tr>
<tr>
<td align="left">Newborns (low birth weight), without bronchopulmonary dysplasia</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">No significant difference in PC between newborns and controls treated with inhaled nitric oxide. Positive correlation between PC and respiratory severity score.</td>
<td align="center">(<xref ref-type="bibr" rid="B8">8</xref>)</td>
</tr>
<tr>
<td align="left">Hepatocellular carcinoma</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">Significantly higher PC in subjects with hepatocellular carcinoma compared with subjects with or without Hepatitis B virus.</td>
<td align="center">(<xref ref-type="bibr" rid="B61">61</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf1">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref> (Supplementary Data are available online at <uri xlink:href="http://www.liebertpub.com/ars" xlink:type="simple">www.liebertpub.com/ars</uri>).</p>
</fn>
<fn id="tf2">
<p>HIV, human immunodeficiency virus; PC, protein carbonyl.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Protein carbonyls increase with age in healthy women and men (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B122">122</xref>). With age, AGEs accumulate in the skin and correlate with the glucose exposure dose in patients on peritoneal dialysis (<xref ref-type="bibr" rid="B25">25</xref>). In diabetes, ROS are generated through several pathways, and elevated AGE concentrations have been reported. Ischemia/reperfusion is clearly associated with oxidative stress. Following coronary surgery in the reperfused human heart, a 2–3-fold increase in protein carbonyls, as measured by ELISA, was observed in plasma isolated from the venous coronary sinus (<xref ref-type="bibr" rid="B130">130</xref>). Protein carbonyls remained increased in blood for up to 18 h and therefore meet one important criterion for being a marker of oxidative stress, which is their stability.</p>
<p>Most methods detect protein carbonyls after derivatization and therefore do not provide a direct measure of these oxidative modifications. While commercial ELISA kits for AGE measurement provide ease of use, many of these do not specify the antibody used, which is just described as polyclonal anti-AGE antibody. This may lead to differences between commercial kits. Nevertheless, protein carbonyls and AGEs have been among the most successful markers of oxidative stress and are associated with disease state and treatment in multiple diseases (<xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>).</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label><sc>Table</sc> 2.</label>
<caption>
<p>
<sc>Selected Clinical Studies of AGE Levels in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease/Condition</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Observation</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf3">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">T2D</td>
<td align="left">Urine, plasma</td>
<td align="left">Stable isotope dilution analysis and LC-MS/MS</td>
<td align="left">Higher basal level in diabetics.</td>
<td align="center">(<xref ref-type="bibr" rid="B57">57</xref>)</td>
</tr>
<tr>
<td align="left">T2D</td>
<td align="left">Skin</td>
<td align="left">SAF</td>
<td align="left">Short-term therapy with benfotiamine did not significantly influence SAF.</td>
<td align="center">(<xref ref-type="bibr" rid="B97">97</xref>)</td>
</tr>
<tr>
<td align="left">T1D, T2D</td>
<td align="left">Skin</td>
<td align="left">SAF</td>
<td align="left">Comparable SAF between children with type I diabetes and nondiabetic adults, indicating chronological aging of the skin.</td>
<td align="center">(88a)</td>
</tr>
<tr>
<td align="left">Diabetes</td>
<td align="left">EDTA plasma, carotid plaque tissue</td>
<td align="left">ELISA, immunohistochemistry</td>
<td align="left">Plasma sRAGE concentrations higher in symptomatic patients.</td>
<td align="center">(<xref ref-type="bibr" rid="B10">10</xref>)</td>
</tr>
<tr>
<td align="left">Acute coronary syndrome</td>
<td align="left">Serum</td>
<td align="left">Competitive ELISA</td>
<td align="left">AGE decreased significantly with statin treatment, AGE levels correlated with plaque progression independently of diabetes.</td>
<td align="center">(<xref ref-type="bibr" rid="B43">43</xref>)</td>
</tr>
<tr>
<td align="left">Chronic kidney disease</td>
<td align="left">Skin</td>
<td align="left">SAF (AGE Reader)</td>
<td align="left">Significantly higher SAF in children with kidney disease in comparison with controls; positive linear correlation between SAF and dialysis treatment duration.</td>
<td align="center">(<xref ref-type="bibr" rid="B62">62</xref>)</td>
</tr>
<tr>
<td align="left">Dialysis</td>
<td align="left">Skin</td>
<td align="left">SAF (AGE Reader)</td>
<td align="left">Accumulation of tissue AGEs is correlated with glucose exposure dose and independently associated with cardiovascular morbidity in patients on peritoneal dialysis.</td>
<td align="center">(<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td align="left">Pancreatic cancer (EPIC study)</td>
<td align="left">Serum</td>
<td align="left">ELISA</td>
<td align="left">Elevated CML was associated with reduced pancreatic cancer risk (the association disappeared after adjustment for HbA1c, BMI, smoking status, and endogenous secreted RAGE).</td>
<td align="center">(<xref ref-type="bibr" rid="B45">45</xref>)</td>
</tr>
<tr>
<td align="left">Pancreatic cancer (ATBC study)</td>
<td align="left">Serum</td>
<td align="left">AGE CML-ELISA</td>
<td align="left">Higher levels of CML-AGE were not associated with a higher risk of pancreatic cancer.</td>
<td align="center">(<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td align="left">PCOS</td>
<td align="left">Serum</td>
<td align="left">Competitive AGE-ELISA</td>
<td align="left">AGEs are elevated in women with PCOS and strongly positively correlated with androgen levels in women with PCOS.</td>
<td align="center">(<xref ref-type="bibr" rid="B37">37</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf3">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>.</p>
</fn>
<fn id="tf4">
<p>AGE, advanced glycation end product; BMI, body–mass index; CML, carboxymethyl lysine; LC, liquid chromatography; MS, mass spectrometry; PCOS, polycystic ovary syndrome; SAF, skin autofluorescence; sRAGE, secreted receptor for AGE; T1D, type 1 diabetes; T2D, type 2 diabetes.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s004">
<title>Oxidized low-density lipoprotein</title>
<p>The measurement of oxidized low-density lipoprotein (oxLDL) as a biomarker of oxidative stress has its origin in the oxidative modification hypothesis of atherosclerosis (<xref ref-type="bibr" rid="B165">165</xref>). However, oxLDL does not chemically define a specific form of modified LDL, molecule, or family of molecules (<xref ref-type="bibr" rid="B166">166</xref>). As the potential of oxLDL as a biomarker for cardiovascular disease (CVD) has been the subject of previous reviews (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B177">177</xref>), we will critically assess the clinical utility of oxLDL as a biomarker.</p>
<p>OxLDL is most commonly measured in plasma or isolated LDL by immunological methods using one of three different antibodies that appear most frequently in the literature: 4E6, DLH3, and E06. The monoclonal antibody, 4E6, binds to aldehyde-modified lysine residues on LDL (<xref ref-type="bibr" rid="B73">73</xref>) and is the basis of a commercial method. The monoclonal antibodies, DLH3 and E06, recognize oxidized phosphatidylcholine (<xref ref-type="bibr" rid="B82">82</xref>) and phosphorylcholine containing short oxidized or nonoxidized side chains, respectively. Plasma oxLDL has been consistently found elevated in patients with CVD, independent of the assay used. However, conflicting results have been reported in studies on the association of oxLDL with atherosclerosis severity and the usefulness of oxLDL for CVD prediction. Contrasting results, depending on the assay, have been reported for plasma oxLDL following pharmacological intervention with statins (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B177">177</xref>). In addition to CVD, plasma oxLDLs are increased in patients with insulin resistance, diabetes, and obesity (<xref ref-type="bibr" rid="B175">175</xref>).</p>
<p>A general limitation of the single most commonly used 4E6-based assay is that native LDL is also detected. As a result, the concentrations of oxLDLs determined closely reflect the concentrations of LDL cholesterol, and the predictive value of the assays is dependent on the levels of apoB (<xref ref-type="bibr" rid="B194">194</xref>). This casts serious doubt over the usefulness of oxLDL as a measure of oxidative stress and its clinical utility to predict cardiovascular and associated diseases above that of LDL cholesterol. Another general problem is that results obtained with different antibodies/methods cannot be compared and often do not correlate with each other, which is inconsistent with oxLDL being a quantitative measure of oxidative stress or representing a meaningful tool to predict CVD. The DLH13-based method was developed for isolated LDL, which limits its clinical utility because LDL isolation is time-consuming and isolated LDL is prone to <italic>ex vivo</italic> oxidation when stored at 4°C or after coating on plates. An extension of this assay to plasma has been developed commercially, but its utility is questionable because plasma and isolated LDL data do not match (<xref ref-type="bibr" rid="B81">81</xref>). A major problem with E06-based methods to determine oxLDL is that contrary to the common notion (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B177">177</xref>), the monoclonal antibody is not specific for oxidized (phospho)lipids (<xref ref-type="bibr" rid="B51">51</xref>) and most of the recognized antigens in plasma reside in lipoproteins other than LDLs (<xref ref-type="bibr" rid="B178">178</xref>).</p>
<p>Given the limitations summarized above, oxLDL is unlikely a specific measure of oxidative stress. This is consistent with the majority of human plasma F<sub>2</sub>-isoprostanes (<xref ref-type="bibr" rid="B202">135a</xref>) and cholesterylester hydroperoxides (<xref ref-type="bibr" rid="B16">16</xref>) being associated with high-density lipoproteins (HDLs) rather than LDLs.</p>
</sec>
<sec id="s005">
<title>Lipid oxidation products</title>
<p>PUFAs, in particular linoleic and arachidonic acid (AA), are important targets of lipid peroxidation. Reaction of ROS, in particular hydroxyl and peroxyl radicals, with bisallylic hydrogen of PUFAs initiates the autocatalytic chain reaction of lipid peroxidation (Reactions 1–3) during which lipid peroxyl radicals act as chain-carrying radicals and lipid hydroperoxides are formed as the primary end products.
<disp-formula><tex-math id="eq1" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\hbox{Initiation \quad\,\,\,LH} + {\rm R}^{\bullet} \rightarrow {\rm L}^{\bullet} + {\rm RH} \tag{1}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq2" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\hbox{Propagation L}^{\bullet} + {\rm O}_2 \rightarrow {\rm LOO}^{\bullet} \tag{2}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq3" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}  {\rm LOO}^{\bullet} + {\rm LH} \rightarrow {\rm LOOH} + {\rm L}^{\bullet} \tag{3}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq4" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\rm {Termination \ LOO}^{\bullet} + {\alpha} \ {\hbox{-}} \
{\rm TOH} \rightarrow {\rm LOOH} + {\alpha} \, {\hbox {-}} {\rm
TO}^{\bullet} \tag{4{\rm a}}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq5" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*} \rm {LOO}^{\bullet} + {\alpha} \ {\hbox{-}} \
{\rm TO}^{\bullet} \rightarrow {\rm NRP} \tag{4{\rm
b}}\end{align*}
\end{document}</tex-math></disp-formula></p>
<p>The chain reaction of lipid peroxidation can be terminated by tocopherols, such as α-tocopherol (α-TOH), <italic>via</italic> reaction with the chain-propagating lipid peroxyl radical (LOO<sup>•</sup>) (Reaction 4a). The resulting α-tocopherol radical (α-TO<sup>•</sup>) can be reduced back to α-TOH by certain reducing agents (<italic>e.g.</italic>, ascorbate) (not shown) or react with a second molecule of LOO<sup>•</sup> to form a nonradical product (NRP) (Reaction 4b).
<disp-formula><tex-math id="eq6" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\quad \quad{\rm LOOH} + {\rm Fe}^{3 +} \rightarrow {\rm LOO}^{\bullet} + {\rm Fe}^{2 +} + {\rm H}^{+} \tag{5}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq7" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\quad\ {\rm LOOH} + {\rm Fe}^{2 +} \rightarrow {\rm LO}^{\bullet} + {\rm Fe}^{3 +} + {^{\bullet}{\rm OH}} \tag{6}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq8" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}\rm {Degradation \ LOO}^{\bullet} \rightarrow
\rightarrow  \rightarrow \rm{reactive \ aldehydes} \\ \ {{(e.g}.,
\rm MDA, \ HNE, \ acrolein)}\tag{7}\end{align*}
\end{document}</tex-math></disp-formula></p>
<p>In the presence of transition metals, lipid hydroperoxides (LOOHs) give rise to LOO<sup>•</sup> (Reaction 5) or lipid alkoxyl radicals (LO<sup>•</sup>) (Reaction 6) that are further cyclized and/or degraded into several different reactive aldehydes (Reaction 7) that participate in various biological processes and signal transduction pathways (<xref ref-type="bibr" rid="B200">200</xref>). Depending on the type of PUFAs undergoing lipid oxidation, these include <italic>trans</italic>-4-hydroxy-2-nonenal (4-HNE), malondialdehyde (MDA), and others. Aldehydes derived from lipids are very reactive and therefore readily react with proteins to form Michael adducts, often denoted as advanced lipoxidation end products (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>Isoprostanes (IsoPs) are formed during free radical-catalyzed oxidation of AA (<xref ref-type="bibr" rid="B119">119</xref>). Radical-mediated oxidation of AA occurs independently of whether it is esterified (as in phospholipids, triacylglycerols, or cholesterylesters). The types of IsoPs that will be formed and in what ratio depend on oxygen tension and glutathione concentration (<xref ref-type="bibr" rid="B120">120</xref>).</p>
</sec>
<sec id="s006">
<title>4-HNE and MDA</title>
<p>Different methods are available for the detection of both MDA and 4-HNE. Antibodies against MDA and 4-HNE bound to different amino acids have been developed (<xref ref-type="bibr" rid="B179">179</xref>, <xref ref-type="bibr" rid="B186">186</xref>) and used in qualitative and semiquantitative immunocyto- and immunohistochemistry, where their presence and relative abundance are detected in cells and tissues in parallel with evaluation of morphological changes (<xref ref-type="bibr" rid="B126">126</xref>). Since Spiteller (<xref ref-type="bibr" rid="B163">163</xref>) reviewed the involvement of lipid peroxidation in a variety of chronic diseases, lipid oxidation end products emerged as oxidative stress markers, with 4-HNE and MDA being among the most investigated (<xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B200">200</xref>) (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" orientation="landscape" position="float">
<label><sc>Table</sc> 3.</label>
<caption>
<p>
<sc>Selected Clinical Studies on 4-HNE, MDA, and F<sub>2</sub>-Isoprostane Levels in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease</italic>
</th>
<th align="center">
<italic>Marker</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Conclusions</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf5">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6">Cardiovascular</td>
</tr>
<tr>
<td align="left"> Ischemic stroke (IS),  post-stroke epilepsy (PSE)</td>
<td align="left">HNE</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">HNE increased in IS and higher in patients with rs671 A allele (ALDH2).</td>
<td align="center">(<xref ref-type="bibr" rid="B112">112</xref>)</td>
</tr>
<tr>
<td align="left"> Acute myocardial infarction</td>
<td align="left">HNE, MDA, lipid hydroperoxides</td>
<td align="left">Plasma</td>
<td align="left">HPLC</td>
<td align="left">Slight increase in infarction.</td>
<td align="center">(<xref ref-type="bibr" rid="B54">54</xref>)</td>
</tr>
<tr>
<td align="left"> Hypertension</td>
<td align="left">MDA, IsoP</td>
<td align="left">Plasma, RBC</td>
<td align="left">HPLC</td>
<td align="left">Hypertension correlates with RBC MDA and plasma IsoP levels.</td>
<td align="center">(<xref ref-type="bibr" rid="B80">80</xref>)</td>
</tr>
<tr>
<td align="left"> Cardiopulmonary bypass</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Plasma</td>
<td align="left">GC-MS</td>
<td align="left">Correlation with decreased dynamic lung compliance.</td>
<td align="center">(<xref ref-type="bibr" rid="B5">5</xref>)</td>
</tr>
<tr>
<td align="left"> Coronary heart disease</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">GC-MS</td>
<td align="left">Independent risk marker for CHD.</td>
<td align="center">(<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B105">105</xref>)</td>
</tr>
<tr>
<td align="left"> Hypercholesterolemia</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Plasma, urine</td>
<td align="left">GC-MS, ELISA</td>
<td align="left">Higher compared with controls. Lowered by statins.</td>
<td align="center">(<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B58">58</xref>)</td>
</tr>
<tr>
<td align="left"> Hypertension</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Plasma, urine</td>
<td align="left">GC-MS, ELISA</td>
<td align="left">Higher in pulmonary and essential hypertension. Lowered by AT1R antagonists.</td>
<td align="center">(<xref ref-type="bibr" rid="B107">107</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Gastrointestinal system</td>
</tr>
<tr>
<td align="left"> Duodenal peptic ulcer</td>
<td align="left">HNE</td>
<td align="left">Tissue</td>
<td align="left">IHC</td>
<td align="left">HNE associated with chronic mucosae alterations due to <italic>H. Pylori.</italic></td>
<td align="center">(<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B113">113</xref>)</td>
</tr>
<tr>
<td align="left"> Crohn's disease</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">GC-MS</td>
<td align="left">Higher in patients.</td>
<td align="center">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Cancer</td>
</tr>
<tr>
<td align="left"> Colon</td>
<td align="left">MDA, HNE</td>
<td align="left">Tissue</td>
<td align="left">HPLC, IHC</td>
<td align="left">HNE and MDA higher in tumor tissue. IHC can distinguish healthy and tumor tissue.</td>
<td align="center">(<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B94">94</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Acrolein</td>
<td align="left">Tissue</td>
<td align="left">HPLC</td>
<td align="left">Indicative of transformation benign to malignant phenotype.</td>
<td align="center">(<xref ref-type="bibr" rid="B115">115</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">LC-MS/MS</td>
<td align="left">No correlation with occurrence of colorectal adenomatous polyps.</td>
<td align="center">(<xref ref-type="bibr" rid="B92">92</xref>)</td>
</tr>
<tr>
<td align="left"> Breast</td>
<td align="left">MDA</td>
<td align="left">Plasma</td>
<td align="left">HPLC</td>
<td align="left">Presurgery MDA prognostic for tumor recurrence.</td>
<td align="center">(<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">HNE</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">HNE-modified PDGF was altered in plasma samples HNE modification of specific proteins.</td>
<td align="center">(<xref ref-type="bibr" rid="B52">52</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">GC-MS</td>
<td align="left">F2-IsoP not different between patients and controls. In women with BMI &gt;29, high F<sub>2</sub>-IsoPs are associated with a higher risk for breast cancer. For women with BMI &lt;23, F<sub>2</sub>-IsoP levels inversely correlated with risk of breast cancer.</td>
<td align="center">(<xref ref-type="bibr" rid="B32">32</xref>)</td>
</tr>
<tr>
<td align="left"> Prostate</td>
<td align="left">Acrolein</td>
<td align="left">Tissue</td>
<td align="left">IHC</td>
<td align="left">Predictive of tumor relapse in combination with clinical parameters.</td>
<td align="center">(<xref ref-type="bibr" rid="B31">31</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">Radioimmunoassay; GC-MS</td>
<td align="left">Conflicting results (either no correlation or positive correlation with risk of prostate cancer.</td>
<td align="center">(<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B44">44</xref>)</td>
</tr>
<tr>
<td align="left"> Brain</td>
<td align="left">HNE</td>
<td align="left">Tissue</td>
<td align="left">IHC</td>
<td align="left">In astrocytic and ependymal glial tumors, HNE is associated with the level of tumor malignancy.</td>
<td align="center">(<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B114">114</xref>)</td>
</tr>
<tr>
<td align="left"> Lung</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">ELISA</td>
<td align="left">Association with lung cancer risk in men.</td>
<td align="center">(<xref ref-type="bibr" rid="B41">41</xref>)</td>
</tr>
<tr>
<td align="left"> Liver</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Urine</td>
<td align="left">ELISA</td>
<td align="left">Association with risk of HCC.</td>
<td align="center">(<xref ref-type="bibr" rid="B110">110</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Neurodegenerative diseases</td>
</tr>
<tr>
<td align="left"> Parkinson's disease</td>
<td align="left">MDA</td>
<td align="left">Plasma</td>
<td align="left">Fluorometric assay</td>
<td align="left">Increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B90">90</xref>)</td>
</tr>
<tr>
<td align="left"> Alzheimer's disease</td>
<td align="left">HNE</td>
<td align="left">Plasma, CSF</td>
<td align="left">Capillary GC/MS</td>
<td align="left">Increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B88">88</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">HNE, MDA</td>
<td align="left">Plasma</td>
<td align="left">Colorimetric assay</td>
<td align="left">HNE, but not MDA, is increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B65">65</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Acrolein, HNE</td>
<td align="left">Tissue</td>
<td align="left">IHC</td>
<td align="left">HNE and acrolein increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td align="left"> Amyotrophic lateral sclerosis</td>
<td align="left">HNE</td>
<td align="left">Serum</td>
<td align="left">HPLC</td>
<td align="left">HNE increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B93">93</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">MDA</td>
<td align="left">Plasma</td>
<td align="left">Fluorometric assay</td>
<td align="left">MDA increased compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B15">15</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Mental</td>
</tr>
<tr>
<td align="left"> Age-related cognitive impairment</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">CSF</td>
<td align="left">GC-MS</td>
<td align="left">Associated with poorer executive function.</td>
<td align="center">(<xref ref-type="bibr" rid="B60">60</xref>)</td>
</tr>
<tr>
<td align="left"> Depression</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Plasma, urine</td>
<td align="left">GC-MS, ELISA</td>
<td align="left">Treatment with bupropion or sertraline decreases symptoms, but increases F<sub>2</sub>-IsoPs.</td>
<td align="center">(<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B40">40</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Multiple</td>
</tr>
<tr>
<td align="left"> Down syndrome</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">Amniotic fluid</td>
<td align="left">ELISA</td>
<td align="left">Increased in pregnancies with Down syndrome fetuses.</td>
<td align="center">(<xref ref-type="bibr" rid="B76">76</xref>)</td>
</tr>
<tr>
<td align="left" colspan="6">Metabolic diseases</td>
</tr>
<tr>
<td align="left"> Diabetes type 2</td>
<td align="left">MDA</td>
<td align="left">Serum</td>
<td align="left">Colorimetric assay</td>
<td align="left">High variability due to age.</td>
<td align="center">(<xref ref-type="bibr" rid="B73">73</xref>)</td>
</tr>
<tr>
<td align="left"> Obesity</td>
<td align="left">HNE</td>
<td align="left">Plasma</td>
<td align="left">HNE-His ELISA</td>
<td align="left">HNE-His increased in obese men.</td>
<td align="center">(<xref ref-type="bibr" rid="B108">108</xref>)</td>
</tr>
<tr>
<td align="left"> Otosclerosis</td>
<td align="left">HNE</td>
<td align="left">Tissue</td>
<td align="left">IHC</td>
<td align="left">HNE associated with the onset of otosclerosis.</td>
<td align="center">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf5">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>.</p>
</fn>
<fn id="tf6">
<p>4-HNE, <italic>trans</italic>-4-hydroxy-2-nonenal; AT1R, angiotensin receptor 1; CHD, coronary heart disease; CSF, cerebrospinal fluid; GC, gas chromatography; F<sub>2</sub>-IsoPs, F<sub>2</sub>-isoprostanes; HCC, hepatocellular carcinoma; HPLC, high-performance liquid chromatography; IHC, immunohistochemistry; IS, ischemic stroke; MDA, malondialdehyde; PDGF, platelet-derived growth factor; PSE, post-stroke epilepsy; RBC, red blood cell.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Despite their widespread use, all methods that detect both MDA and 4-HNE have their pitfalls (<xref ref-type="bibr" rid="B162">162</xref>). In the thiobarbituric acid reactive substances (TBARS) assay, up to 98% of the measured MDA can be formed by the high-temperature conditions during the procedure itself (<xref ref-type="bibr" rid="B117">117</xref>). When combined with HPLC, MDA-TBA adducts in <italic>in vitro</italic> oxidized human plasma can be determined reproducibly and reliably, although this method requires individual sample processing and its validity as a marker of <italic>in vivo</italic> oxidative stress remains uncertain, making it less applicable for routine clinical use (<xref ref-type="bibr" rid="B19">19</xref>). The numerous commercial easy-to-use kits lack specificity and their significance for clinical research is questionable.</p>
<p>In general, direct MDA and 4-HNE measurement is insensitive as the vast majority of these reactive products are bound to proteins and other biomolecules and remain undetected unless released before the assay (<xref ref-type="bibr" rid="B49">49</xref>). To measure the presence of 4-HNE in biological samples, including protein-bound aldehydes, protein immunodetection is preferred, either applied as immunohistochemistry or as HNE-His ELISA (<xref ref-type="bibr" rid="B187">187</xref>). The specificity of the monoclonal antibodies against HNE-His adducts allows their use in human and animal tissues, tissue homogenates, and in plasma and serum samples (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B162">162</xref>).</p>
</sec>
<sec id="s007">
<title>F<sub>2</sub>-isoprostanes</title>
<p>Several thorough reviews of the biochemistry and utility of F<sub>2</sub>-isoprostanes (F<sub>2</sub>-IsoPs) as biomarkers have been recently published (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>), so only the most seminal points will be summarized here. Oxidation of AA forms a family of 64 bicyclic endoperoxide regio- and stereoisomers collectively termed H<sub>2</sub>-isoprostanes (<xref ref-type="bibr" rid="B140">140</xref>). Nonenzymatic rearrangement of these H<sub>2</sub>-isoprostanes forms both stable F<sub>2</sub>-IsoPs and highly reactive γ-ketoaldehydes termed isolevuglandins (IsoLGs, also known as isoketals) (<xref ref-type="bibr" rid="B115">115</xref>). Because of their chemical stability and sensitivity to changes in oxidative stress, F<sub>2</sub>-IsoPs are often considered the most reliable markers for monitoring oxidative stress <italic>in vivo</italic> (<xref ref-type="bibr" rid="B89">89</xref>). Elevated concentrations of F<sub>2</sub>-IsoPs are found in CVD, correlate with extent of disease, and predict the outcome (<xref ref-type="bibr" rid="B39">39</xref>). Elevated F<sub>2</sub>-IsoPs are also found in a wide range of human clinical conditions (<xref ref-type="bibr" rid="B113">113</xref>).</p>
<p>Despite strong evidence for their utility as biomarkers (<xref ref-type="table" rid="T3">Table 3</xref>), one challenge to widespread adaptation of F<sub>2</sub>-IsoPs in clinical trials is that the most reliable methods for their quantitation, gas chromatography–mass spectrometry (GC-MS) and LC-MS/MS, are labor-intensive and require specialized and expensive instrumentation (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B114">114</xref>). While commercial immunoassays have been developed as a cheaper and easier alternative to mass spectrometry (MS), the results obtained with these immunoassays often do not correlate well with those obtained with GC-MS (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B136">136</xref>). Thus, the results from immunoassays, particularly for individual patients, must be used with extreme caution, only with appropriate sample cleanup, and validated by MS whenever possible.</p>
</sec>
<sec id="s008">
<title>Isolevuglandins</title>
<p>Similar to F2-IsoPs, IsoLGs are products derived from the oxidation of AA and are sensitive to changes in oxidative stress. While F<sub>2</sub>-IsoPs are stable products of lipid oxidation, IsoLGs (<xref ref-type="fig" rid="f4">Fig. 4</xref>) react rapidly and irreversibly with primary amines (<italic>e.g.</italic>, protein lysyl residues and phosphatidylethanolamine) in the cell to form pyrrole (lactam) and oxidized pyrrole (hydroxylactam) adducts (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B146">146</xref>). Thus, only IsoLG adducts, and not unreacted IsoLGs, are detected in cells and tissues.</p>
<fig fig-type="figure" id="f4" orientation="portrait" position="float">
<label>
<bold>FIG. 4.</bold>
</label>
<caption>
<p><bold>Regioisomers of isolevuglandins.</bold> Specific IsoLG regioisomers differ by the relative orientation of their keto- and aldehyde moieties (D<sub>2</sub>-IsoLG <italic>vs.</italic> E<sub>2</sub>-IsoLG) and the position of the double bonds and hydroxyl group on the side chains (5-, 8-, 12-, or 15-IsoLG) (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B147">147</xref>, <xref ref-type="bibr" rid="B148">148</xref>). Theoretical considerations from peroxidation chemistry suggest that the 5- and 15-IsoLG series should predominate over the 8- and 12-IsoLG series (<xref ref-type="bibr" rid="B198">198</xref>). It is important to recognize that one of the eight stereoisomers of both 15-D<sub>2</sub>-IsoLG and 15-E<sub>2</sub>-IsoLG is chemically identical to levuglandin D<sub>2</sub> and E<sub>2</sub>, respectively, which are generated nonenzymatically from prostaglandin H<sub>2</sub> (<xref ref-type="bibr" rid="B149">149</xref>, <xref ref-type="bibr" rid="B150">150</xref>). IsoLG, isolevuglandins.</p>
</caption>
<graphic xlink:href="fig-4"></graphic>
</fig>
<p>IsoLG adducts may eventually prove to have greater utility as disease biomarkers than more generalized measures of oxidative stress status because they appear to directly participate in pathological processes. The biological effects of exogenous IsoLGs on cultured cells include induction of inflammatory pathways, immune responses, and cell death, as well as inhibiting ion channel function (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B95">95</xref>). These results, along with the therapeutic effects of administering small-molecule IsoLG scavengers in animal models, suggest that IsoLGs could contribute to disease processes, including inflammation, hypertension, arrhythmia, atherosclerosis, and neurodegeneration (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B146">146</xref>).</p>
<p>Quantitative immunoassays using polyclonal antibodies against IsoLG-protein adducts detected increased IsoLG-protein adduct formation in plasma from patients with atherosclerosis, in plasma from patients with end-stage renal disease, and in the glaucomatous trabecular meshwork (<xref ref-type="bibr" rid="B146">146</xref>). Immunohistochemical staining with the single-chain antibody D11ScFv that selectively recognized IsoLG-protein adducts showed increased adducts in the epicardial border zone of myocardial infarcts (<xref ref-type="bibr" rid="B56">56</xref>), in the hippocampus of Alzheimer's disease patients (<xref ref-type="bibr" rid="B38">38</xref>), and in heart, aorta, and dendritic cells during hypertension (<xref ref-type="bibr" rid="B64">64</xref>).</p>
<p>Mass spectrometric methods have demonstrated increased IsoLG-protein adducts compared with controls in the epicardial border zone of myocardial infarcts (<xref ref-type="bibr" rid="B56">56</xref>), in the hippocampus of Alzheimer's patients (<xref ref-type="bibr" rid="B38">38</xref>), and dendritic cells during hypertension (<xref ref-type="bibr" rid="B64">64</xref>). Using MS, IsoLG-phosphatidylethanolamine adducts have been found to be increased in plasma from patients with macular degeneration (<xref ref-type="bibr" rid="B102">102</xref>).</p>
<p>Currently, there are no published studies demonstrating that increased levels of IsoLG adducts predict onset or severity of subsequent disease. Therefore, the utility of measuring IsoLG adducts in urine or plasma as clinical biomarkers remains to be established. Nevertheless, current findings provide strong rationale for further investigation of the potential use of IsoLG adducts as clinical biomarkers, both to identify persons at risk and to determine the efficacy of treatments targeting IsoLGs such as dicarbonyl scavengers.</p>
</sec>
<sec id="s009">
<title>3-Nitrotyrosine</title>
<p>Nitrotyrosine (Tyr-NO<sub>2</sub>) is often described as a stable marker of oxidative/nitrative stress in inflammatory diseases (<xref ref-type="bibr" rid="B71">71</xref>). Tyrosine nitration involves the replacement of C<sub>3</sub> hydrogen atom of the tyrosine aromatic ring with a nitro group (R-NO<sub>2</sub>) (<xref ref-type="bibr" rid="B11">11</xref>) (<xref ref-type="fig" rid="f5">Fig. 5</xref>). This modification can occur within a polypeptide sequence (protein-associated Tyr-NO<sub>2</sub>) or to free tyrosine amino acids (free Tyr-NO<sub>2</sub>). Nitration can occur by several pathways <italic>in vivo</italic>, but always involves RNS and is usually a two-step process (<xref ref-type="bibr" rid="B161">161</xref>), in which (i) tyrosine is oxidized resulting in a tyrosine radical and (ii) a radical–radical reaction occurs between the tyrosine radical and nitrogen dioxide (<sup><bold>•</bold></sup>NO<sub>2</sub>). It is possible for the tyrosine radical to react with nitric oxide (<sup><bold>•</bold></sup>NO), followed by further oxidation to yield Tyr-NO<sub>2</sub>, but this pathway has not been well studied (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<fig fig-type="figure" id="f5" orientation="portrait" position="float">
<label>
<bold>FIG. 5.</bold>
</label>
<caption>
<p><bold>Structure of 3-nitrotyrosine.</bold> Tyrosine nitration involves the replacement of the C<sub>3</sub> hydrogen atom of the tyrosine aromatic ring with a nitro group (R-NO<sub>2</sub>). The 3-nitrotyrosine is depicted as part of a polypeptide/protein.</p>
</caption>
<graphic xlink:href="fig-5"></graphic>
</fig>
<p>One widely studied pathway for nitration is the production of the RNS peroxynitrite (ONOO<sup>−</sup>) (<xref ref-type="fig" rid="f6">Fig. 6</xref>, pathway 1) (<xref ref-type="bibr" rid="B132">132</xref>). Initially, Tyr-NO<sub>2</sub> was believed to be a specific marker of peroxynitrite-mediated damage, but this has since been disproved, with the most-cited alternate pathway involving myeloperoxidase (MPO), as proposed in 1997 (<xref ref-type="bibr" rid="B183">183</xref>) (<xref ref-type="fig" rid="f6">Fig. 6</xref>, pathway 2). When solely measuring Tyr-NO<sub>2</sub> in complex biological samples, it is not possible to tell which of the mechanisms is responsible for any nitration detected <italic>in vivo</italic>. The effect of nitration on protein activity varies with the protein being studied and can be a gain of function (<xref ref-type="bibr" rid="B180">180</xref>) or loss of function (<xref ref-type="bibr" rid="B195">195</xref>).</p>
<fig fig-type="figure" id="f6" orientation="portrait" position="float">
<label>
<bold>FIG. 6.</bold>
</label>
<caption>
<p><bold>Formation of nitrotyrosine.</bold> In pathway 1, peroxynitrite is formed by the reaction of <sup><bold>•</bold></sup>NO with the superoxide anion radical (O<sub>2</sub><sup><bold>•−</bold></sup>). The enzymatic generation of both these radicals is increased during inflammation. Radical–radical combination of the two species occurs exceedingly fast (rate constant 1 × 10<sup>10</sup> M<sup>−1</sup>s<sup>−1</sup>), meaning that <sup><bold>•</bold></sup>NO can outcompete the dismutation of O<sub>2</sub><sup><bold>•</bold>−</sup> by SODs (<xref ref-type="bibr" rid="B138">138</xref>). Under physiological conditions in which CO<sub>2</sub> is present, nitration <italic>via</italic> peroxynitrite is increased (<xref ref-type="bibr" rid="B3">3</xref>) due to the formation of the adduct ONOOCO<sub>2</sub><sup>−</sup>. This adduct undergoes homolysis to the secondary free radicals, nitrogen dioxide (<sup><bold>•</bold></sup>NO<sub>2</sub>) and carbonate anion radical (CO<sub>3</sub><sup><bold>•</bold>−</sup>) (<xref ref-type="bibr" rid="B132">132</xref>). CO<sub>3</sub><sup><bold>•−</bold></sup> is able to perform <italic>step 1</italic> of the nitration process by oxidizing tyrosine to tyrosine radical, which then reacts with the <bold><sup>•</sup></bold>NO<sub>2</sub>. In pathway 2, MPO catalyzes, in the presence of H<sub>2</sub>O<sub>2</sub> and nitrite (NO<sub>2</sub><sup><bold>−</bold></sup>), the production of both the tyrosine radical and <sup><bold>•</bold></sup>NO<sub>2</sub> (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B132">132</xref>). CO<sub>2</sub>, carbon dioxide; ONOOCO<sub>2</sub>, nitrosoperoxocarbonate; SODs, superoxide dismutases.</p>
</caption>
<graphic xlink:href="fig-6"></graphic>
</fig>
<p>The issue of which method to employ for the determination of Tyr-NO<sub>2</sub> in the high-throughput analysis of clinical samples needs be addressed as MS, while considered the gold standard (<xref ref-type="bibr" rid="B176">176</xref>), is not yet feasible for high-throughput analysis and other methods suffer from methodological flaws or cannot be properly assessed due to a lack of detailed methodological information (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B197">197</xref>). In addition, some authors fail to clearly state whether free Tyr-NO<sub>2</sub>, protein-associated Tyr-NO<sub>2</sub>, or total Tyr-NO<sub>2</sub> is measured, the concentrations of which may be different. While evidence does suggest that nitration of certain proteins enhances proteolytic degradation (<xref ref-type="bibr" rid="B160">160</xref>), a fall in protein-associated Tyr-NO<sub>2</sub> concentration will only be measurable if the nitrated protein is degraded in parallel with a decrease in disease activity.</p>
<p>There is still much work to do in assessing the utility of Tyr-NO<sub>2</sub> as a clinical biomarker, but findings so far are encouraging, with some studies showing that plasma Tyr-NO<sub>2</sub> levels correlate with disease activity and decrease following successful therapeutic interventions. Yet, it is still unclear whether Tyr-NO<sub>2</sub> is any more informative, in clinical terms, than other already available markers, for example, C-reactive protein (CRP). CRP is an acute phase protein synthesized by the liver in response to signaling by upregulated inflammatory cytokines (<italic>e.g.</italic>, IL-6). Serum CRP is widely used clinically as a marker of acute inflammation, but of course an increase in serum CRP concentration is delayed until some hours after the initial inflammatory insult because liver synthesis of CRP protein is required. In contrast, chemical modifications to pre-existing cellular or extracellular proteins may occur more swiftly within an inflammatory environment. One application where the measurement of Tyr-NO<sub>2</sub> might provide a significant enhancement is in the monitoring of clinical responses to therapy in the assessment of the current pipeline of novel drugs targeted at enzymes involved in ROS generation, for example, NADPH oxidase and MPO inhibitors.</p>
<p>Tyr-NO<sub>2</sub> can be detected in tissues by various methods. Among the quantitative approaches, both ELISAs and LC/GC have been described; however, it is important to note that quantification by ELISAs is limited by several factors: (i) antibodies employed in ELISAs will have different affinities for different nitrated proteins (<xref ref-type="bibr" rid="B94">94</xref>), although this is addressed by methods that measure a single nitrated protein (<xref ref-type="bibr" rid="B188">188</xref>); (ii) some Tyr-NO<sub>2</sub> ELISAs may be prone to interference; and (iii) the sensitivity of some Tyr-NO<sub>2</sub> ELISAs may be too low to detect Tyr-NO<sub>2</sub> in healthy human plasma. LC/GC has been coupled to various detection systems, for example, UV detection, thermal energy analysis, electrochemical detection, and MS. One explanation for the lack of agreement between reported plasma ELISA- and MS-based Tyr-NO<sub>2</sub> plasma concentrations is that the reported ELISA results are based on a nitrated bovine serum albumin standard, in which the actual concentration of nitrated tyrosine residues is unknown.</p>
<p>The National Institute of Environmental Health Biomarkers of Oxidative Stress Study concluded that oxidized proteins (of which Tyr-NO<sub>2</sub> was one of the measured biomarkers) are not suitable biomarkers of free radical damage caused by carbon tetrachloride treatment in rats (<xref ref-type="bibr" rid="B89">89</xref>). Nevertheless, many studies have investigated Tyr-NO<sub>2</sub> under inflammatory conditions as a marker of oxidative stress and have found plasma Tyr-NO<sub>2</sub> concentrations to be higher in patients in a variety of diseases (summarized in <xref ref-type="table" rid="T4">Table 4</xref>). Some of the clinically relevant findings include the association of higher Tyr-NO<sub>2</sub> levels with higher mortality in sepsis and a fall in plasma Tyr-NO<sub>2</sub> concentration, as well as a correlation with other markers following treatment with various anti-inflammatory drugs. In addition, two studies using different methodologies reported a lowering of plasma protein-associated Tyr-NO<sub>2</sub> concentrations upon drug treatment (statins in coronary artery disease and rosuvastatin in hypercholesterolemia). Tyr-NO<sub>2</sub> may not only be a potential biomarker of oxidative stress in diabetes patients (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>) but may also be a biomarker of disease progression/risk for CVD (<xref ref-type="bibr" rid="B201">111a</xref>). In asthmatic patients, Tyr-NO<sub>2</sub> staining in bronchial biopsies and measurement of Tyr-NO<sub>2</sub> by ELISA in exhaled breath condensates both showed a decrease of Tyr-NO<sub>2</sub> upon corticosteroid treatment. Conflicting results were obtained in neurodegenerative disorders; although Tyr-NO<sub>2</sub> has been reported at increased levels within brain tissue from Parkinson's (<xref ref-type="bibr" rid="B60">60</xref>) and Alzheimer's disease patients (<xref ref-type="bibr" rid="B167">167</xref>), free Tyr-NO<sub>2</sub> is not increased in the cerebrospinal fluid of Alzheimer's disease patients (<xref ref-type="bibr" rid="B143">143</xref>). Likewise, protein-bound Tyr-NO<sub>2</sub> is not increased in plasma of patients with dementia (<xref ref-type="bibr" rid="B44">44</xref>). In contrast, nitrated α-synuclein was detected in peripheral blood mononuclear cells from Parkinson's disease patients, the concentrations of which were inversely correlated with the daily dosage of levodopa (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap id="T4" orientation="landscape" position="float">
<label><sc>Table</sc> 4.</label>
<caption>
<p>
<sc>Selected Clinical Studies on Nitrotyrosine Levels in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease/Condition</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Observation</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf7">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">CAD</td>
<td align="left">Plasma</td>
<td align="left">LC-MS/MS</td>
<td align="left">Reduction in protein-associated Tyr-NO<sub>2</sub> following rosuvastatin treatment.</td>
<td align="center">(<xref ref-type="bibr" rid="B91">91</xref>)</td>
</tr>
<tr>
<td align="left">CAD</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">Protein-associated Tyr-NO<sub>2</sub> is a robust predictor of CAD in patients with abnormal glucose tolerance.</td>
<td align="center">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td align="left">Hypercholesterolemia</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">Reduction in protein-associated Tyr-NO<sub>2</sub> following statin treatment; this lowering effect was independent of the fall in lipid parameters and CRP.</td>
<td align="center">(<xref ref-type="bibr" rid="B77">77</xref>)</td>
</tr>
<tr>
<td align="left">Asthma</td>
<td align="left">Bronchial biopsies</td>
<td align="left">Immunohistochemical staining</td>
<td align="left">Reduction of Tyr-NO<sub>2</sub> staining after treatment with inhaled glucocorticoid compared with before treatment.</td>
<td align="center">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td align="left">Asthma</td>
<td align="left">Exhaled breath condensates</td>
<td align="left">ELISA</td>
<td align="left">Protein-associated Tyr-NO<sub>2</sub> levels decrease following steroid treatment and increase again following a washout period.</td>
<td align="center">(<xref ref-type="bibr" rid="B13">13</xref>)</td>
</tr>
<tr>
<td align="left">Asthma</td>
<td align="left">Exhaled breath condensates</td>
<td align="left">ELISA</td>
<td align="left">Protein-associated Tyr-NO<sub>2</sub> levels are higher in mild asthmatics who were not receiving steroid treatment than in patients with moderate/severe asthma who were receiving treatment.</td>
<td align="center">(<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td align="left">Atherosclerosis</td>
<td align="left">Coronary artery; plasma</td>
<td align="left">Immunohistochemical staining; Western blot</td>
<td align="left">Apo-AI nitration at tyrosine-166 leads to functional impairment and is increased in atherosclerotic coronary arteries compared with normal coronary arteries.</td>
<td align="center">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left">Pulmonary hypertension</td>
<td align="left">Lung tissue</td>
<td align="left">Immunohistochemical staining</td>
<td align="left">Nitration of protein kinase G at tyrosine-247 inhibits its activity and is increased in the lung in patients with pulmonary hypertension compared with healthy controls.</td>
<td align="center">(<xref ref-type="bibr" rid="B4">4</xref>)</td>
</tr>
<tr>
<td align="left">Septic shock</td>
<td align="left">Plasma</td>
<td align="left">Amino acid analyzer</td>
<td align="left">Concentrations of free Tyr-NO<sub>2</sub> are associated with prognosis in patients with septic shock, with higher levels observed in those who did not survive than those who did.</td>
<td align="center">(<xref ref-type="bibr" rid="B72">72</xref>)</td>
</tr>
<tr>
<td align="left">OA, RA</td>
<td align="left">Serum, synovial fluid</td>
<td align="left">HPLC</td>
<td align="left">RA patients have detectable free Tyr-NO<sub>2</sub> in plasma and synovial fluid, but not healthy subjects or OA patients. Patients with lower RA disease stage had lower free Tyr-NO<sub>2</sub>.</td>
<td align="center">(<xref ref-type="bibr" rid="B55">55</xref>)</td>
</tr>
<tr>
<td align="left">OA, RA</td>
<td align="left">Plasma, synovial fluid</td>
<td align="left">LC-MS/MS</td>
<td align="left">Increased levels of total Tyr-NO<sub>2</sub> and higher ratio of synovial/serum total Tyr-NO<sub>2</sub> in OA compared with healthy controls. Lowering of total Tyr-NO<sub>2</sub> concentrations after 6 months of anti-TNF treatment, which was associated with a change in the RA disease activity score.</td>
<td align="center">(<xref ref-type="bibr" rid="B66">66</xref>)</td>
</tr>
<tr>
<td align="left">OA</td>
<td align="left">Serum</td>
<td align="left">ELISA</td>
<td align="left">Nitrated collagen concentrations are higher in patients with OA compared with healthy control participants. Concentration of collagen-associated Tyr-NO<sub>2</sub> correlated with the serum concentration of CRP.</td>
<td align="center">(<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td align="left">Celiac disease</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">Reduction in protein-associated Tyr-NO<sub>2</sub> concentrations following a gluten-free diet.</td>
<td align="center">(<xref ref-type="bibr" rid="B96">96</xref>)</td>
</tr>
<tr>
<td align="left">SLE</td>
<td align="left">Serum</td>
<td align="left">ELISA</td>
<td align="left">Significantly higher levels of protein-associated Tyr-NO<sub>2</sub> in patients with a disease activity score greater than six (SLE Disease Activity Index).</td>
<td align="center">(<xref ref-type="bibr" rid="B106">106</xref>)</td>
</tr>
<tr>
<td align="left">Parkinson's disease</td>
<td align="left">Peripheral blood mononuclear cells</td>
<td align="left">ELISA</td>
<td align="left">Observation of nitrated α-synuclein, the concentration of which was inversely correlated with daily dosage of levodopa.</td>
<td align="center">(<xref ref-type="bibr" rid="B78">78</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf7">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>.</p>
</fn>
<fn id="tf8">
<p>CAD, coronary artery disease; CRP, C-reactive protein; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s010">
<title>Thiols</title>
<p>The main thiol compound in the body is the amino acid cysteine, which is susceptible to oxidation. Oxidation of a cysteine residue can change a protein's function. Thus, measuring the thiol status may represent a mechanism-based biomarker. Biologically occurring thiols include low-molecular-weight thiols (cysteine, GSH) and protein thiols.</p>
<p>The use of thiols as biomarkers is affected by a number of factors. In addition to specific limitations for those thiols that are only present intracellularly, a general problem is that oxidation products of protein cysteine residues are unstable. They can be easily reduced by other thiols and thus require immediate treatment with an alkylating agent to prevent further redox changes. A change in GSH levels might not be due to oxidative stress, but might reflect a nutritional/metabolic imbalance. Plasma GSH levels may also be affected by GSH transporters, while cellular mechanisms, such as nuclear factor (erythroid-derived 2)-like 2 (NRF2), counteract oxidative stress by increasing GSH synthesis. Finally, oxidized glutathione (GSSG) concentrations are very low and difficult to measure unless sensitive HPLC methods are used.</p>
</sec>
<sec id="s011">
<title>Glutathione</title>
<p>The main nonprotein thiol is the tripeptide GSH. Since intracellular concentrations of GSH are high, in the millimolar range, it is an important component of antioxidant defense systems to scavenge ROS, which leads to GSSG. Oxidation of GSH is reversible as GSSG reductase and NADPH reduce GSSG back to two molecules of GSH.</p>
<p>In general, any condition associated with excessive ROS will decrease GSH levels or decrease the GSH/GSSG ratio. Within cells, GSH is present at millimolar concentrations, resulting in high GSH/GSSG ratios (&gt;30) (<xref ref-type="bibr" rid="B76">76</xref>). The GSH/GSSG ratio in serum is substantially lower (∼3). Whether this meaningfully reflects a cellular redox state is questionable (<xref ref-type="bibr" rid="B90">90</xref>) and it may not be a good indicator of oxidative stress (<xref ref-type="bibr" rid="B86">86</xref>). Thus, most studies measure erythrocyte GSH where GSH concentrations are high, but not necessarily a good indicator of oxidative stress across tissues. Furthermore, lower GSH levels may not necessarily be due to oxidation, but rather due to a consequence of lower cysteine levels (cysteine is the rate-limiting GSH precursor) due to nutritional deficiency. Nevertheless, many studies have measured plasma GSH/GSSG. Three meta-analyses confirmed a decrease in plasma GSH and an increase in plasma GSSG in patients with autism spectrum disorders (<xref ref-type="bibr" rid="B54">54</xref>) and lower plasma GSH levels in polycystic ovary syndrome (<xref ref-type="bibr" rid="B121">121</xref>), two conditions in which oxidative stress has been implicated (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B144">144</xref>). It should be noted that these meta-analyses are based on studies where GSH/GSSG are measured by a variety of techniques, including enzymatic methods, HPLC with fluorometric, UV, or electrochemical detectors, and LC-MS/MS.</p>
<p>Several pathological conditions are associated with decreased GSH levels (<xref ref-type="bibr" rid="B6">6</xref>). In particular, studies on GSH in acquired immunodeficiency syndrome (AIDS) and other conditions have shown very clearly that rather than in plasma, GSH should be measured within cells by fluorescence activated cell sorting (<xref ref-type="bibr" rid="B72">72</xref>). GSH measurement is important to identify patients who may benefit from GSH repletion by GSH derivatives or precursors, for example, in clinical trials (<xref ref-type="bibr" rid="B6">6</xref>).</p>
</sec>
<sec id="s012">
<title>Cysteine</title>
<p>Free cysteine is the main nonprotein thiol in plasma (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B118">118</xref>). Studies have measured plasma cysteine (∼10 μ<italic>M</italic>) and its disulfide, cystine (∼40–50 μ<italic>M</italic>), in CVDs with varying results (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B112">112</xref>). Cysteine is a semiessential amino acid and its requirement may increase following oxidative stress due to the consumption of GSH (<xref ref-type="bibr" rid="B6">6</xref>). Historically, one important condition associated with lower plasma cysteine is AIDS, originally reported by the group of Droge (<xref ref-type="bibr" rid="B46">46</xref>).</p>
</sec>
<sec id="s013">
<title>Protein thiols and mixed disulfides</title>
<p>Protein cysteine residues can exist in many oxidation states (<xref ref-type="fig" rid="f7">Fig. 7</xref>). Protein glutathionylation (mixed disulfides with GSH) received particular attention. Significant amounts of glutathionylated proteins are detected under normal conditions or following exposure to oxidants (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B156">156</xref>). Most of the glutathionylated proteins are intracellular because GSH is predominantly present in the cytoplasm and intracellular proteins have cysteine residues predominantly in the chemically reduced state and thus are available to form mixed disulfides, in contrast to extracellular proteins where most cysteine residues are engaged in disulfide bridges.</p>
<fig fig-type="figure" id="f7" orientation="portrait" position="float">
<label>
<bold>FIG. 7.</bold>
</label>
<caption>
<p><bold>Protein cysteine oxidation states.</bold> Cysteine residues in proteins can exist in different oxidation states, ranging from reduced free thiols to reversible oxidized forms (disulfides, S-nitrosothiols, sulfenic acids, and sulfinic acids) to irreversible sulfonic acids. *Reversibility of protein cysteine sulfinic acids has so far been demonstrated only for some sulfinylated peroxiredoxins and requires the enzymatic activity of sulfiredoxin.</p>
</caption>
<graphic xlink:href="fig-7"></graphic>
</fig>
<p>The only plasma protein identified as glutathionylated is transthyretin (<xref ref-type="bibr" rid="B58">58</xref>). Many studies propose glutathionylated hemoglobin, measured in red blood cells by MS, as a biomarker of oxidative stress in diabetes, hyperlipidemia, hemodialysis, and chronic renal failure (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B58">58</xref>). An increase in plasma cysteinylated albumin, measured by MS, has also been reported in chronic liver and kidney diseases and diabetes (<xref ref-type="bibr" rid="B124">124</xref>).</p>
</sec>
<sec id="s014">
<title>Surface thiols</title>
<p>The plasma membrane is the interface between the reducing intracellular and the oxidizing extracellular environments. While one might expect the extracellular (exofacial) membrane thiols to be oxidized, they are in fact not, and active mechanisms maintain specific surface thiols (<xref ref-type="bibr" rid="B98">98</xref>), with surface thiols lower in rheumatoid arthritis (RA) (<xref ref-type="bibr" rid="B131">131</xref>). Their measurement may provide additional information on the redox state of a patient (<xref ref-type="bibr" rid="B145">145</xref>).</p>
</sec>
<sec id="s015">
<title>Methionine sulfoxide</title>
<p>Methionine is the other sulfur-containing amino acid beside cysteine (<xref ref-type="fig" rid="f8">Fig. 8</xref>). Sulfur in methionine can be reversibly oxidized by ROS to a sulfoxide. Oxidation of an essential methionine in the abundant serum protein α-1-proteinase inhibitor leads to its inactivation (<xref ref-type="bibr" rid="B85">85</xref>). Elevated levels of this sulfoxidized form have been detected in the bronchoalveolar lavage of smokers, contributing to the pathogenesis of emphysema (<xref ref-type="bibr" rid="B27">27</xref>). The presence of methionine sulfoxide in plasma proteins and in HDL is increased in sepsis and diabetes (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Although not as widely studied as a form of thiol oxidation, methionine sulfoxide has potential advantages as a biomarker: it is easily measured with a conventional amino acid analyzer and is more stable than thiol oxidation products.</p>
<fig fig-type="figure" id="f8" orientation="portrait" position="float">
<label>
<bold>FIG. 8.</bold>
</label>
<caption>
<p><bold>Structure of methionine sulfoxide.</bold> Methionine contains a sulfur atom that is also susceptible to oxidation and can give rise to methionine sulfoxide. The methionine sulfoxide is depicted as part of a polypeptide/protein.</p>
</caption>
<graphic xlink:href="fig-8"></graphic>
</fig>
</sec>
<sec id="s016">
<title>DNA/RNA oxidation</title>
<p>Oxidative stress induces oxidation of DNA and RNA (<xref ref-type="fig" rid="f9">Fig. 9</xref>), particularly in the guanine moiety. The oxidized nucleosides are excreted into the urine and their measurement can be interpreted as the cumulative total body oxidative stress, that is, number of hits to the nucleic acids in a defined time period, meaning the global rate of DNA and RNA oxidation. Therefore, as urinary biomarkers, they are most relevant to conditions where oxidative stress occurs in all tissues in the body and less to high oxidative stress in minor organs without assumed systemic oxidative stress. Several commercial assays are available to measure 7,8-dihydro-8-oxo-2′-deoxyguanosine (8oxodG) with ELISA. However, the clinical significance of these methods has been questioned (<xref ref-type="bibr" rid="B10">10</xref>). While chromatography coupled to MS may not be readily available clinically, biomarkers for oxidative stress measured by oxidation of nucleic acids are among—if not the best—biomarkers that have been examined. Nucleic acid oxidation products have also been demonstrated to be predictive of the development of disease (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>).</p>
<fig fig-type="figure" id="f9" orientation="portrait" position="float">
<label>
<bold>FIG. 9.</bold>
</label>
<caption>
<p><bold>Structure of 8-oxo-2′-deoxyguanosine and 8-oxo-guanosine.</bold> Oxidation of DNA and RNA commonly occurs in the guanosine moiety, leading to 8-oxo-2′-deoxyguanosine and 8-oxo-guanosine, respectively.</p>
</caption>
<graphic xlink:href="fig-9"></graphic>
</fig>
<p>The oxidative modification in DNA can cause mispair and thereby lead to mutations, particularly GC-TA transversion mutations, and therefore relates to cancer (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B134">134</xref>). Oxidative lesions in DNA are recognized by repair enzymes; the nucleotide pool can be oxidized, but is sanitized by other enzyme systems (<xref ref-type="bibr" rid="B133">133</xref>). There is some debate as to whether the lesions in DNA relate to incorporation from the nucleotide pool or direct oxidation in DNA (<xref ref-type="bibr" rid="B70">70</xref>). Chronically high oxidation of DNA, measured as urinary excretion of the nucleoside 8oxodG, is associated with risk of lung and breast cancer (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B105">105</xref>).</p>
<p>Recently, RNA oxidation, measured as 7,8-dihydro-8-oxo-guanosine (8oxoGuo), has been introduced as a marker in relation to diseases, particularly neurodegenerative diseases and diabetes (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Because of the single strand nature of RNA, repair is not possible. Remarkably, relatively little is known about how RNA integrity is maintained, but it is assumed to rely on quality control and degradation (<xref ref-type="bibr" rid="B133">133</xref>). The cellular effects of RNA oxidation also remain largely obscure, although formation of truncated or mutated proteins has been suggested (<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B135">135</xref>). There are indications of formation of mutated proteins (<xref ref-type="bibr" rid="B170">170</xref>) and of microsomal stalling induced by oxidized RNAs (<xref ref-type="bibr" rid="B159">159</xref>). Very recently, advanced methodology has demonstrated that the effects of RNA lesions fall into two categories, one that includes ribosomal stalling and one that leads to a mixture of full length and truncated translational products (<xref ref-type="bibr" rid="B26">26</xref>). It thus appears that nucleic acid oxidation/modification has much more diverse and multifaceted biological effects, exemplified both with different effects on translation stalling and also in the target molecule, for example, in diabetes where RNA oxidation is not only more pronounced than DNA oxidation but also has a very different prognostic value.</p>
<p>Extensive DNA oxidation is predictive for the risk of breast and lung cancer (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B105">105</xref>). Elevated RNA oxidation is predictive for development of complications and death in type 2 diabetes, and there are indications that high RNA oxidation is associated with breast cancer development in type 2 diabetic females (<xref ref-type="bibr" rid="B22">22</xref>). Thus, screening for urinary DNA/RNA oxidation could help to identify such people and patients at risk and help to implement a treatment plan to minimize it.</p>
<p>For measurement of 8oxodG and 8oxoGuo in urine, the most reliable methodology is chromatography coupled with MS (<xref ref-type="bibr" rid="B189">189–191</xref>). 8oxodG can also be measured by HPLC-electrochemical detection, which is rarely used presently.</p>
</sec>
</sec>
<sec id="s017">
<title>Markers of ROS Generation</title>
<p>Some ROS-forming enzymes that are normally present intracellularly can also be found in the circulation, independently of the mechanism responsible for their release. For this reason, we will only describe xanthine oxidase (XO) and MPO. Higher circulating levels of XO and MPO could potentially result in increased ROS production, although this depends on other factors such as availability of the substrate (xanthine for XO and H<sub>2</sub>O<sub>2</sub> for MPO) and whether ROS produced by these enzymes overcome the antioxidant defense. In some cases, a better indicator of the enzyme activity <italic>in vivo</italic> is the formation of the metabolite or reaction product.</p>
<sec id="s018">
<title>Xanthine oxidase</title>
<p>XO catalyzes the oxidation of xanthine to uric acid. While the product is a known antioxidant (<xref ref-type="bibr" rid="B4">4</xref>), the enzyme is also a well-known source of O<sub>2</sub><sup><bold>⋅</bold></sup><sup>−</sup> (<xref ref-type="bibr" rid="B109">109</xref>). Inflammatory agents and interferon increase XO activity and its plasma levels (<xref ref-type="bibr" rid="B59">59</xref>). However, the most important translational breakthrough was the hypothesis of the role of XO in ischemia–reperfusion injury (<xref ref-type="bibr" rid="B108">108</xref>). This led to several, ongoing clinical trials with XO inhibitors in CVD and prompted many studies to measure circulating XO (<xref ref-type="bibr" rid="B12">12</xref>). It should be mentioned that XO inhibition has other effects than inhibiting ROS production. In particular, by decreasing uric acid, it may improve CVD by lowering hyperuricemia (<xref ref-type="bibr" rid="B14">14</xref>), and uric acid is not only an antioxidant (<xref ref-type="bibr" rid="B4">4</xref>) but also proinflammatory through activation of the NALP3 inflammasome (<xref ref-type="bibr" rid="B107">107</xref>).</p>
<p>While we list XO among the ROS-generating enzymes, it could also be an indicator of oxidative stress. In fact, the protein exists in two forms, an oxidase (that oxidizes xanthine to uric acid using oxygen as the electron acceptor and produces H<sub>2</sub>O<sub>2</sub>) and a dehydrogenase (that carries out the same reaction, but uses NAD<sup>+</sup> and generates NADH). The dehydrogenase form can be converted into XO by, among other things, thiol oxidation (<xref ref-type="bibr" rid="B48">48</xref>). Thus, oxidative stress will increase XO activity by increasing dehydrogenase-to-oxidase conversion.</p>
</sec>
<sec id="s019">
<title>Myeloperoxidase</title>
<p>MPO is a heme peroxidase that catalyzes the reaction between H<sub>2</sub>O<sub>2</sub> and chloride ions to produce HOCl as the primary oxidant. These are not only important in the innate immune system's antimicrobial activities but also contribute to inflammatory diseases, such as atherosclerosis and related vascular diseases (<xref ref-type="bibr" rid="B35">35</xref>) and Parkinson's and Alzheimer's disease (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B123">123</xref>, <xref ref-type="bibr" rid="B139">139</xref>), <italic>via</italic> multiple mechanisms (<xref ref-type="bibr" rid="B166">166</xref>).</p>
<p>The suitability of MPO as a potential independent prognostic biomarker of inflammation is summarized in <xref ref-type="table" rid="T5">Table 5</xref>. A limitation of MPO as a biomarker is that current methods are not standardized between laboratories and do not provide direct information on MPO activity. The methods used to directly measure MPO activity as well as biomarkers specific for MPO have been reviewed recently (<xref ref-type="bibr" rid="B92">92</xref>). MPO-derived oxidants generate a footprint of specific and nonspecific oxidation products. 3-Chlorotyrosine (3-Cl-Tyr) and chlorinated lipids, as well as glutathione sulfonamide, are specific products for MPO/HOCl (<xref ref-type="bibr" rid="B92">92</xref>). Nonspecific oxidation products include protein carbonyls and 3-nitrotyrosine modifications. Of the specific biomarkers, 3-Cl-Tyr has received the most attention and has been detected in a wide variety of diseases (<xref ref-type="table" rid="T6">Table 6</xref>).</p>
<table-wrap id="T5" orientation="portrait" position="float">
<label><sc>Table</sc> 5.</label>
<caption>
<p>
<sc>Selected Clinical Studies on MPO Levels in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease/Condition</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Observation</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf9">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Cardiovascular disease</td>
<td align="left">Serum</td>
<td align="left">High-sensitivity sandwich ELISA</td>
<td align="left">MPO independently predicted endothelial dysfunction better than CRP.</td>
<td align="center">(<xref ref-type="bibr" rid="B103">103</xref>)</td>
</tr>
<tr>
<td align="left">Acute coronary syndrome</td>
<td align="left">Serum</td>
<td align="left">ELISA</td>
<td align="left">Increased risk for future cardiac events in patients with elevated serum MPO.MPO, soluble CD40 ligand, and TnT are independent predictors of adverse outcome.</td>
<td align="center">(<xref ref-type="bibr" rid="B7">7</xref>)</td>
</tr>
<tr>
<td align="left">Acute chest pain, incident MACE</td>
<td align="left">Plasma</td>
<td align="left">Commercial immuno-based assay</td>
<td align="left">MPO higher in MACE patients at hospitalization. MPO predictive for MACE in patients with normal cardiac TnT.</td>
<td align="center">(<xref ref-type="bibr" rid="B71">71</xref>)</td>
</tr>
<tr>
<td align="left">Cardiovascular disease (LURIC study)</td>
<td align="left">Plasma</td>
<td align="left">ELISA (MPO) and PCR (MPO polymorphisms)</td>
<td align="left">High MPO predicted mortality independent of established cardiovascular risk factors. Five of eight MPO polymorphisms associated with increased MPO. No association of MPO genotype with mortality.</td>
<td align="center">(<xref ref-type="bibr" rid="B84">84</xref>)</td>
</tr>
<tr>
<td align="left">Major adverse cardiac events</td>
<td align="left">Plasma</td>
<td align="left">Commercial immuno-based assay</td>
<td align="left">MPO included in CBS used to predict future MACEs. High CBS predicted increased risk of MACEs at 3 years.</td>
<td align="center">(<xref ref-type="bibr" rid="B98">98</xref>)</td>
</tr>
<tr>
<td align="left">Major adverse cardiac events</td>
<td align="left">Plasma</td>
<td align="left">Commercial immuno-based assay</td>
<td align="left">Patient with MPO &gt;322 pmol/L had increased risk of developing future MACE.</td>
<td align="center">(<xref ref-type="bibr" rid="B100">100</xref>)</td>
</tr>
<tr>
<td align="left">Chest pain</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">MPO elevated at baseline and 2 h after onset of symptoms, correlated with TnT concentration, and is an independent predictor of MI and CVD risk.</td>
<td align="center">(<xref ref-type="bibr" rid="B16">16</xref>)</td>
</tr>
<tr>
<td align="left">Myocardial infarction</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">MPO increased and independently predicted development of myocardial infarction in the ensuing 24 months.</td>
<td align="center">(<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td align="left">Myocardial infarction</td>
<td align="left">Plasma</td>
<td align="left">ELISA</td>
<td align="left">MPO higher in patients than controls and a predictor of death or nonfatal MI.</td>
<td align="center">(<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td align="left">Heart failure</td>
<td align="left">Plasma</td>
<td align="left">Cardio MPO test</td>
<td align="left">High plasma MPO independently predicted the development of heart failure in apparently healthy elderly subjects.</td>
<td align="center">(<xref ref-type="bibr" rid="B99">99</xref>)</td>
</tr>
<tr>
<td align="left">Peripheral artery disease</td>
<td align="left">Serum</td>
<td align="left">Solid-phase sandwich ELISA</td>
<td align="left">High MPO associated with low ankle-brachial index and PAD independent of CRP.</td>
<td align="center">(<xref ref-type="bibr" rid="B6">6</xref>)</td>
</tr>
<tr>
<td align="left">Obesity, cardiovascular disease</td>
<td align="left">Plasma</td>
<td align="left">Particle-enhanced turbidimetric immunoassay</td>
<td align="left">MPO, IL-6, and TNF-α were higher in obese than control children and associated with higher cardiovascular risk compared with control.</td>
<td align="center">(<xref ref-type="bibr" rid="B74">74</xref>)</td>
</tr>
<tr>
<td align="left">Chronic obstructive pulmonary disease</td>
<td align="left">Serum</td>
<td align="left">ELISA</td>
<td align="left">MPO increased in patients during acute exacerbations and persisted for months following acute illness.</td>
<td align="center">(<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td align="left">Alzheimer's disease</td>
<td align="left">Plasma</td>
<td align="left">Sandwich ELISA</td>
<td align="left">MPO positively associated with the presence of Alzheimer's disease, correlated with Aβ<sub>1-42/1-40</sub> ratio, and may potentially be an ideal biomarker for Alzheimer's disease.</td>
<td align="center">(<xref ref-type="bibr" rid="B101">101</xref>)</td>
</tr>
<tr>
<td align="left">Cognitive decline</td>
<td align="left">Plasma</td>
<td align="left">Sandwich ELISA</td>
<td align="left">Biomarkers of low-grade inflammation, including MPO, and endothelial dysfunction correlated with increased vascular risk and reduced cognitive ability in an older population.</td>
<td align="center">(<xref ref-type="bibr" rid="B48">48</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf9">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary information</xref>.</p>
</fn>
<fn id="tf10">
<p>CBS, cardiac biomarker score; CVD, cardiovascular disease; IL-6, interleukin-6; MACE, major adverse cardiac event; MI, myocardial infarct; MPO, myeloperoxidase; PAD, peripheral artery disease; PCR, polymerase chain reaction; TnT, troponin T.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T6" orientation="portrait" position="float">
<label><sc>Table</sc> 6.</label>
<caption>
<p>
<sc>Selected Clinical Studies on Specific Markers of MPO Activity in Different Diseases</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Disease/Condition</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Method</italic>
</th>
<th align="center">
<italic>Observation</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf11">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Acute myocardial infarction</td>
<td align="left">Plasma</td>
<td align="left">ELISA (MPO), HPLC (3-Cl-Tyr)</td>
<td align="left">Plasma MPO and 3 Cl-Tyr increased in AMI, and AMI incidence increased with higher MPO and 3-Cl-Tyr.</td>
<td align="center">(<xref ref-type="bibr" rid="B26">26</xref>)</td>
</tr>
<tr>
<td align="left">Coronary artery disease, Acute coronary syndrome</td>
<td align="left">Plasma, HDL</td>
<td align="left">Turbidimetric immunoassay (MPO)<break></break>LC-MS/MS (3 Cl-Tyr)</td>
<td align="left">No difference in plasma MPO, but increased 3-Cl-Tyr in HDL of subjects with CAD/ACS. HDL-associated 3-Cl-Tyr may be a better biomarker of CAD/ACS than plasma MPO.</td>
<td align="center">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td align="left">CVD</td>
<td align="left">apoB-100</td>
<td align="left">LC-MS/MS</td>
<td align="left">Different apoB-100-derived peptides with modifications characteristic of active MPO are present in humans with increased risk for CVD.</td>
<td align="center">(<xref ref-type="bibr" rid="B35">35</xref>)</td>
</tr>
<tr>
<td align="left">Rheumatoid arthritis</td>
<td align="left">Synovial fluid</td>
<td align="left">ELISA (MPO), LC-MS/MS (3 Cl-Tyr)</td>
<td align="left">MPO higher in patients than controls. MPO protein 20-fold higher in synovial fluid compared with plasma in RA. 3-Cl-Tyr detected in synovial fluid of patients with rheumatoid arthritis.</td>
<td align="center">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td align="left">Rheumatoid arthritis</td>
<td align="left">HDL</td>
<td align="left">MS/MS</td>
<td align="left">Subjects with RA have increased 3-Cl-Tyr and Tyr-NO<sub>2</sub> in HDL. MPO-mediated HDL oxidation is regiospecific in RA and further exacerbated with cardiovascular disease.</td>
<td align="center">(<xref ref-type="bibr" rid="B104">104</xref>)</td>
</tr>
<tr>
<td align="left">Rheumatoid arthritis, Osteoarthritis</td>
<td align="left">Synovial fluid</td>
<td align="left">Spectrophotometer (α<sub>2</sub>M) and GC-MS (3 Cl-Tyr)</td>
<td align="left">α<sub>2</sub>M more oxidized and inactivated in RA, and 3-Cl-Tyr elevated in RA compared with OA.</td>
<td align="center">(<xref ref-type="bibr" rid="B111">111</xref>)</td>
</tr>
<tr>
<td align="left">Preterm infants</td>
<td align="left">Tracheal aspirate</td>
<td align="left">LC-MS/MS</td>
<td align="left">3-Cl-Tyr concentration was elevated in infants who developed chronic lung disease or had lung infection.</td>
<td align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf11">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>.</p>
</fn>
<fn id="tf12">
<p>AMI, acute myocardial infarction; ACS, acute coronary syndrome; HDL, high-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Chlorinated lipids have been detected in human atherosclerotic plaque (<xref ref-type="bibr" rid="B173">173</xref>). 2-Chloradipic acid (<xref ref-type="bibr" rid="B185">185</xref>) is excreted in urine and hence offers the potential as a biomarker. Glutathione sulfonamide is present in the airways of preterm infants with respiratory disease as well as in children suffering from cystic fibrosis (<xref ref-type="bibr" rid="B93">93</xref>).</p>
<p>A general limitation of the specific biomarkers of MPO activity is the requirement for expensive equipment and time-consuming sample workup and analysis. Often, concentration of these biomarkers in biological samples is low, which complicates accurate measurement. As a result, investigators have fractionated plasma and observed that HDL can be the major carrier of 3-Cl-Tyr in CVD (<xref ref-type="bibr" rid="B15">15</xref>). However, the extensive preparation procedures for HDL analysis limit its clinical use. Glutathione sulfonamide is a relatively minor oxidation product derived from the reaction of reduced glutathione (GSH) with HOCl. This limits its application to biological samples that contain significant amounts of GSH. Plasma, which has very little GSH, is therefore not a suitable source to analyze glutathione sulfonamide.</p>
<p>Within these limitations, the determination of MPO protein is a reasonable approach to at least initially assess a potential contribution of MPO-mediated oxidative damage to a disease, and in most studies, MPO and specific MPO activity biomarkers with different specificities provide similar results (<xref ref-type="table" rid="T5">Tables 5</xref> and <xref ref-type="table" rid="T6">6</xref>).</p>
</sec>
</sec>
<sec id="s020">
<title>Markers of Antioxidant Defense</title>
<p>In principle, oxidative stress can also derive from an impaired antioxidant defense. We focus here not only on protein thiol-disulfide oxidoreductases that can be measured in serum or plasma but also the transcription factor NRF2 that drives the transcription of several antioxidant genes. NRF2 is activated in response to oxidative stress and its activation could therefore be used as an indicator of ROS generation that exceeded the existing antioxidant defense systems.</p>
<sec id="s021">
<title>Protein thiol-disulfide oxidoreductases</title>
<p>These enzymes include, among others, thioredoxin (Trx) and peroxiredoxins (Prxs; <xref ref-type="fig" rid="f10">Fig. 10</xref>). Trx main function is to keep protein thiols in the reduced state. For this reason, Trx is often regarded as an antioxidant enzyme. Secretion of Trx was originally discovered in leukemia cells by virologist Junji Yodoi, who initially thought he had identified interleukin-1-γ (<xref ref-type="bibr" rid="B199">199</xref>). While it cannot be excluded that Trx secretion may be induced by other factors, it is thought that its secretion is induced by oxidative stress. Its secretion is inhibited by antioxidants <italic>in vitro</italic> (<xref ref-type="bibr" rid="B96">96</xref>) and its plasma levels are elevated in cancer patients (<xref ref-type="bibr" rid="B8">8</xref>) and AIDS patients, where it negatively correlates with survival (<xref ref-type="bibr" rid="B125">125</xref>). Various reports have suggested that plasma/serum Trx concentrations are diagnostically relevant in a range of diseases. For instance, Qi <italic>et al.</italic> found that serum Trx concentrations reflected disease severity in acute ischemic stroke (<xref ref-type="bibr" rid="B137">137</xref>), and the addition of Trx to an established disease severity score provided a significant improvement in diagnostic capacity.</p>
<fig fig-type="figure" id="f10" orientation="portrait" position="float">
<label>
<bold>FIG. 10.</bold>
</label>
<caption>
<p><bold>Protein thiol-disulfide oxidoreductases regulate the redox state of protein thiols.</bold> Different thiol compounds can be present under different redox states, depending on the overall redox state of the cell, from the more reduced (<italic>left</italic>) to more oxidized (<italic>right</italic>), and the significance of a specific biomarker will depend on its intracellular localization, tissue expression, and redox potential.</p>
</caption>
<graphic xlink:href="fig-10"></graphic>
</fig>
<p>The Prx family has a key role in the elimination of H<sub>2</sub>O<sub>2</sub> because it is highly abundant and reacts with H<sub>2</sub>O<sub>2</sub> at high rates. Prxs are often identified in proteomics studies and several studies identified Prxs in the secretome under various disease conditions (<xref ref-type="bibr" rid="B80">80</xref>). In particular, oxidized Prx6 in the cerebrospinal fluid has been proposed as a biomarker of oxidative stress in brain injury, where it is a good predictor of the outcome (<xref ref-type="bibr" rid="B106">106</xref>). The importance of the redox state of Prxs as biomarkers is also demonstrated by studies showing that Prx2 is secreted <italic>via</italic> a nonclassical pathway by inflammatory cells (<xref ref-type="bibr" rid="B151">151</xref>) independently of cell death (<xref ref-type="bibr" rid="B30">30</xref>) and is present in the serum and synovial fluid of RA patients (<xref ref-type="bibr" rid="B168">168</xref>). Bayer <italic>et al.</italic> (<xref ref-type="bibr" rid="B13">13</xref>) have shown <italic>in vivo</italic> that erythrocyte Prx2 undergoes a transient overoxidation following lipopolysaccharide exposure, and released Prx1/2 is present in the oxidized form (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B151">151</xref>), suggesting that its redox state, not just its levels, can be an early marker of oxidative stress.</p>
<p>Human serum Prx4 has also been proposed as a diagnostic marker of oxidative stress in diabetes (<xref ref-type="bibr" rid="B1">1</xref>).</p>
</sec>
<sec id="s022">
<title>Nuclear factor (erythroid-derived 2)-like 2</title>
<p>The transcription factor NRF2 is considered a prognostic biomarker in cancer. It is found constitutively and at very high levels in biopsies of malignant tumors with high proliferation rates and poor response to anticancer drugs. NRF2 is a master regulator of the antioxidant response that controls the expression of about 250 genes. Some of these genes encode antioxidant enzymes, including those involved in synthesis and use of GSH and Trx, or participate in metabolic reactions that generate reductive power in the form of NADPH. Others participate in phase II biotransformation reactions and phase III external transport of toxins. Thus, high and constitutive activity of NRF2 provides transformed cells with a defense against the ROS that are generated during active proliferation, while at the same time reducing the effective dose of certain anticancer drugs. To date, a prognostic value of NRF2 has been reported for adenocarcinoma (<xref ref-type="bibr" rid="B79">79</xref>), squamous cell carcinoma (<xref ref-type="bibr" rid="B75">75</xref>), colon (<xref ref-type="bibr" rid="B84">84</xref>), lung (<xref ref-type="bibr" rid="B196">196</xref>), and breast cancer (<xref ref-type="bibr" rid="B129">129</xref>), among many others. NRF2 does not initiate carcinogenesis, but potentiates tumor promotion or metastasis. Somatic mutations in the NRF2 gene and in its repressor, KEAP1, have been found in a large percentage of human tumors, leading to constitutively increased NRF2 levels (<xref ref-type="bibr" rid="B68">68</xref>). Moreover, malignant transformation elicited by some oncogenes such as KRAS (<xref ref-type="bibr" rid="B42">42</xref>) or loss of tumor suppressor PTEN (<xref ref-type="bibr" rid="B142">142</xref>) leads to abnormally high levels of NRF2 protein and activity. Thus, analysis of NRF2 levels by either immunoblot or qRT-PCR in tumor biopsies is becoming a tool to clinically assess tumor malignancy.</p>
<p>NRF2 activity declines with age as well as in degenerative disorders. Considering that NRF2 is being validated as an antioxidant and immunomodulator target for diseases with an autoimmune component or with low-grade chronic inflammation, it will be necessary to develop reliable predictive markers that help to monitor effective targeting. The most significant advancement in development of these prospective biomarkers has been in patients with chronic obstructive pulmonary disorder. In a small cohort of these patients, it was reported that dietary administration of sulforaphane-rich broccoli sprout extract for two weeks enhanced the mRNA levels of several NRF2-regulated genes in peripheral blood mononuclear cells (<xref ref-type="bibr" rid="B67">67</xref>).</p>
</sec>
</sec>
<sec id="s023">
<title>Downstream Functional Markers of ROS-Induced Damage</title>
<p>The biomarkers described above are indicative of increased ROS levels, either by increased formation or decreased removal. An alternative would be markers that reflect oxidative stress downstream of the ROS-induced damage. Ideally, this marker would be a direct risk factor so that its modulation by therapeutic interventions would predict a positive outcome. Two markers appear to qualify for this, asymmetric dimethyl L-arginine (ADMA) and phosphorylated vasodilator-stimulated phosphoprotein (P-VASP).</p>
<sec id="s024">
<title>Asymmetric dimethyl L-arginine</title>
<p>ADMA is a ubiquitous metabolite derived from protein modification and degradation. Upon accumulation, it can interfere with arginine metabolism and <sup><bold>•</bold></sup>NO formation by endothelial <sup><bold>•</bold></sup>NO synthase (NOS) eNOS/NOS3 (<xref ref-type="bibr" rid="B182">182</xref>), and plasma ADMA concentrations correlate with endothelial, kidney, and erectile dysfunction (<xref ref-type="bibr" rid="B100">100</xref>), as well as heart failure (<xref ref-type="bibr" rid="B66">66</xref>). Plasma ADMA concentrations are significantly associated with every disease of the cardiovascular system, showing an independent, strong prognostic value for mortality and future cardiovascular events. However, non-CVDs with a possible deregulation of NOS have not been studied in great detail. ADMA is either excreted by cationic amino acid transporters that supply intracellular NOS with its substrate, L-arginine, and then eliminated by the kidney or metabolized to L-citrulline by <italic>N<sup>G</sup>-N<sup>G</sup></italic>-dimethylarginine dimethylaminohydrolase (DDAH) (<xref ref-type="bibr" rid="B171">171</xref>). DDAH has an active site cysteine residue that can be a direct target of oxidative or nitrosative modification (<xref ref-type="bibr" rid="B99">99</xref>), resulting in the inhibition of ADMA degradation. Increased intracellular ADMA levels may be the reason for the observed therapeutic effects of L-arginine (<xref ref-type="bibr" rid="B153">153</xref>, <xref ref-type="bibr" rid="B154">154</xref>) (see the accompanying ARS FORUM review on Therapeutics).</p>
</sec>
<sec id="s025">
<title>Phosphorylated vasodilator-stimulated phosphoprotein</title>
<p>The best-established marker for physiological cyclic guanosine monophosphate (cGMP) signaling is probably P-VASP. It is phosphorylated mainly by cGMP-dependent protein kinases (<xref ref-type="bibr" rid="B25">25</xref>), and lowered P-VASP levels are indicative of pathological signaling (<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B110">110</xref>). This pathological signaling can be brought about by oxidative stress, for example, through scavenging of <sup><bold>•</bold></sup>NO by superoxide or direct oxidation of soluble guanylate cyclase (sGC), both of which limit the level of sGC activation and cGMP production (<xref ref-type="fig" rid="f2">Fig. 2</xref>). However, in human blood samples, for example, in platelets, P-VASP levels can be utilized to establish the efficacy of (or detect nonresponders to) antiplatelet drugs (<xref ref-type="bibr" rid="B57">57</xref>), to detect physiological responses to NO donors and hence the presence of sGC (<xref ref-type="bibr" rid="B155">155</xref>), or to identify pathological responses to sGC activators as an indirect assay of increased oxidized/apo-sGC levels (<xref ref-type="bibr" rid="B2">2</xref>) (see the accompanying ARS Forum review on Targets).</p>
</sec>
</sec>
<sec id="s026" sec-type="conclusion">
<title>Conclusion</title>
<p>The markers discussed here have been studied in different disease settings and with different rigor, ranging from meta-analyses of several clinical studies to promising evidence in preclinical studies (<xref ref-type="table" rid="T7">Table 7</xref>). However, even when the highest evidence level is available, their specificity as a biomarker of oxidative stress could be questionable, as in the case of oxLDL. Oxidative stress likely plays a role in several diseases, yet very few oxidative stress markers have made it into routine clinical use, which may have several reasons. The properties of the oxidative modifications, such as the labile nature of cysteine modifications, or their low abundance poses significant challenges to translate them into a high-throughput, cost-effective clinical diagnostic. Stable oxidative modifications, such as protein carbonyls, certain lipid oxidation products, DNA/RNA oxidation, and 3-nitrotyrosine, certainly circumvent the first issue, which likely contributes to some of their positive clinical findings. Another limitation is methodology. While MS provides sensitivity and specificity and has become more accessible, antibody-based methods remain, for now, the clinical standard. However, as we have seen, some of these methods fall short on specificity, such as antibodies specific for oxLDL, and any new antibody-based marker requires rigorous testing for specificity and sensitivity. Other antibody-based methods, such as immunohistochemistry, require tissues that are not commonly accessible. Circulating cell harvesting methods may provide a future solution to this. For a new biomarker to be established for clinical use, it would also require additional benefit over established clinical markers. Paradoxically, this additional value of oxidative stress biomarkers may come from being indicators of a disease mechanism common to several pathologies rather than diagnostic for a specific disease. Oxidative stress biomarkers may help in identifying patient populations that benefit from certain treatments, allowing patient stratification based on pathogenic mechanisms rather than just disease severity, thus responding to a specific request from regulatory agencies (<xref ref-type="bibr" rid="B47">47</xref>). On the other hand, protein-specific modifications such as nitrotyrosine could be disease-specific biomarkers of oxidative stress (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap id="T7" orientation="landscape" position="float">
<label><sc>Table</sc> 7.</label>
<caption>
<p>
<sc>Overview of Highest Evidence Levels for All Discussed Markers</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left"> </th>
<th align="left"> </th>
<th align="left"> </th>
<th align="left"> </th>
<th align="left"> </th>
<th align="center" colspan="2">
<italic>Basis for evidence level</italic>
</th>
</tr>
<tr>
<th align="left">
<italic>Evidence level category (A–D)</italic>
</th>
<th align="center">
<italic>Biomarker</italic>
</th>
<th align="center">
<italic>Gold standard</italic>
</th>
<th align="center">
<italic>Sample</italic>
</th>
<th align="center">
<italic>Stability</italic>
</th>
<th align="center">
<italic>Disease</italic>
</th>
<th align="center">
<italic>Reference</italic>
<sup>
<xref ref-type="table-fn" rid="tf13">a</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">A</td>
<td align="left">Protein carbonyls</td>
<td align="left">ELISA/HPLC</td>
<td align="left">Plasma</td>
<td align="left">Months to years (-80C)</td>
<td align="left">MCI</td>
<td align="center">(<xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">AGE</td>
<td align="left">None</td>
<td align="left">Plasma, skin</td>
<td align="left">Not known</td>
<td align="left">PCOS, T2D, CKD</td>
<td align="center">(<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B62">62</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">Ox-LDL</td>
<td align="left">ELISA</td>
<td align="left">Plasma</td>
<td align="left">Not known</td>
<td align="left">AD</td>
<td align="center">(<xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">4-HNE</td>
<td align="left">IHC/HIS-ELISA</td>
<td align="left">Tissue, plasma</td>
<td align="left">Years, months (-80C)</td>
<td align="left">Cancer (brain, breast), obesity</td>
<td align="center">(<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B114">114</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">Acrolein</td>
<td align="left">IHC</td>
<td align="left">Formalin-fixed tissue</td>
<td align="left">Years</td>
<td align="left">Prostate carcinoma</td>
<td align="center">(<xref ref-type="bibr" rid="B31">31</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">MDA</td>
<td align="left">HPLC</td>
<td align="left">EDTA plasma</td>
<td align="left">Months (-80C)</td>
<td align="left">PCOS, AD, MCI</td>
<td align="center">(<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">F<sub>2</sub>-IsoP</td>
<td align="left">GC-MS, LC-MS/MS</td>
<td align="left">Plasma, urine, tissue</td>
<td align="left">Months (-80C)</td>
<td align="left">Depression</td>
<td align="center">(<xref ref-type="bibr" rid="B12">12</xref>)</td>
</tr>
<tr>
<td align="left">D</td>
<td align="left">IsoLGs</td>
<td align="left">LC-MS/MS</td>
<td align="left">Tissue, plasma</td>
<td align="left">Months (-80C)</td>
<td align="left">Several preclinical</td>
<td align="center">Multiple, see main text</td>
</tr>
<tr>
<td align="left">B</td>
<td align="left">Protein-Tyr-NO<sub>2</sub></td>
<td align="left">LC-MS/MS, GC-MS/MS</td>
<td align="left">Tissue, plasma</td>
<td align="left">Weeks to months (-80C)</td>
<td align="left">Diabetes</td>
<td align="center">(<xref ref-type="bibr" rid="B22 B23 B24 B25">22–25</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">GSH</td>
<td align="left">LC-MS/MS, HPLC</td>
<td align="left">Tissue, plasma?</td>
<td align="left">Short</td>
<td align="left">ASD; PCOS</td>
<td align="center">(<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B68">68</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">P-SSG (hemoglobin)</td>
<td align="left">LC-MS/MS</td>
<td align="left">Tissue, plasma?</td>
<td align="left">Short</td>
<td align="left">T2D, CRF</td>
<td align="center">(<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B83">83</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">Thioredoxin</td>
<td align="left">ELISA</td>
<td align="left">Plasma</td>
<td align="left">Years (-80C)</td>
<td align="left">CPB, AIDS</td>
<td align="center">(<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">Peroxiredoxin</td>
<td align="left">ELISA</td>
<td align="left">Plasma</td>
<td align="left">Years (-80C)</td>
<td align="left">CHD, T2D</td>
<td align="center">(<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">8oxodG</td>
<td align="left">UPLC-MS/MS</td>
<td align="left">Urine</td>
<td align="left">Years</td>
<td align="left">Depression</td>
<td align="center">(<xref ref-type="bibr" rid="B12">12</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">8oxoGuo</td>
<td align="left">UPLC-MS/MS</td>
<td align="left">Urine</td>
<td align="left">Years</td>
<td align="left">T2D, AD, MCI</td>
<td align="center">(<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td align="left">B</td>
<td align="left">MPO</td>
<td align="left">ELISA</td>
<td align="left">Plasma</td>
<td align="left">Months</td>
<td align="left">AMI</td>
<td align="center">(<xref ref-type="bibr" rid="B26">26</xref>)</td>
</tr>
<tr>
<td align="left">B</td>
<td align="left">3-Cl-Tyr</td>
<td align="left">LC-MS/MS</td>
<td align="left">Many</td>
<td align="left">Months</td>
<td align="left">Atherosclerosis, RA</td>
<td align="center">(<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B104">104</xref>)</td>
</tr>
<tr>
<td align="left">C</td>
<td align="left">NRF2</td>
<td align="left">IHC/qRT-PCR</td>
<td align="left">Tissue</td>
<td align="left">Years (IHC), months (PCR)</td>
<td align="left">Various cancers</td>
<td align="center">Multiple, see main text</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">P-VASP</td>
<td align="left">Immunolabeling with FC</td>
<td align="left">Platelets</td>
<td align="left">24–48 h</td>
<td align="left">PCI/clopidogrel resistance</td>
<td align="center">(<xref ref-type="bibr" rid="B14">14</xref>)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">ADMA</td>
<td align="left">LC-MS/MS</td>
<td align="left">Plasma</td>
<td align="left">Months (-20C)</td>
<td align="left">PCOS, CVD</td>
<td align="center">(<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B109">109</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf13">
<label>
<sup>a</sup>
</label>
<p>References are provided as <xref ref-type="supplementary-material" rid="SD1">supplementary information</xref>.</p>
</fn>
<fn id="tf14">
<p>Categories are based on the following evidence levels: (A) Meta-analysis or large prospective studies, (B) Prospective studies, (C) Retrospective studies, and (D) Case reports or preclinical studies.</p>
</fn>
<fn id="tf15">
<p>AD, Alzheimer's disease; ADMA, asymmetric dimethyl L-arginine; AIDS, acquired immunodeficiency syndrome; ASD, autism spectrum disorders; CKD, chronic kidney disease; CPB, cardiopulmonary bypass; CRF, chronic renal failure; FC, flow cytometry; IsoLG, isolevuglandins; MCI, myocardial infarction; ox-LDL, oxidized LDL; PCI, percutaneous coronary intervention; qRT-PCR, quantitative real time polymerase chain reaction; UPLC, ultra performance LC.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s027">
<title>Outlook</title>
<p>One way forward may be the analysis of oxidative stress markers for specific proteins. Such markers might better represent an underlying specific disease mechanism and a means for therapeutic monitoring and outcome prediction. In addition, as many of the markers have been measured in similar diseases, a combination of them in large-scale panels and pattern analysis could provide an additional approach to measure disease progression or therapeutic outcome (<xref ref-type="fig" rid="f3">Fig. 3</xref>). This will help overcome the problem of the fragmentation of the literature in the field as different markers of oxidative stress are measured in different diseases. Measurement of larger panels of biomarkers in key conditions will help give a more comprehensive picture of their significance. In parallel with the exciting developments on ROS-validated targets and clinical indications, those markers and patterns that correlate best with treatment efficacy or mortality will eventually advance the field of ROS biomarkers, for example, in the form of theranostic couples of a new drug comarketed with a diagnostic marker.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<caption>
<title>Supplemental data</title>
</caption>
<media id="d37e4475" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="Supp_Data.pdf" xlink:type="simple"></media>
</supplementary-material>
</sec>
</body>
<back>
<sec id="s028" sec-type="ack">
<title>Acknowledgments</title>
<p>The authors acknowledge financial support from the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS) (P.G.W., N.Z., T.R., A.C., H.E.P., H.H.H.W.S., P.G.), the Peptide Research Network of Excellence, European Cross-border Cooperation Programme INTERREG IV A France (Channel)-England, ERDF (P.G.), the Toyota foundation, Denmark (H.E.P.), a Senior Principal Research Fellowship from the National Health and Medical Research Council and National Health and Medical Research Council Project Grants 1020776 and 1060804 (R.S.), and National Institutes of Health Grant HL116263 (S.S.D.). A.K. is supported by a grant from the Defence Science and Technology Laboratory, United Kingdom, to P.G.W. and E.L.T.</p>
</sec>
<ref-list content-type="parsed">
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Corpeleijn</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gansevoort</surname><given-names>RT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gans</surname><given-names>ROB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Struck</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schulte</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hillege</surname><given-names>HL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van der Harst</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stolk</surname><given-names>RP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Navis</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bakker</surname><given-names>SJL</given-names></name></person-group>
<article-title>Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study</article-title>. <source/>Diabetologia
<volume>57</volume>: <fpage>1842</fpage>–<lpage>1849</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24893865</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrens</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Habersberger</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baumlin</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Qian</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>BK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stasch</surname><given-names>J-P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bode</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HHHW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Peter</surname><given-names>K</given-names></name></person-group>
<article-title>Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC</article-title>. <source/>Atherosclerosis
<volume>218</volume>: <fpage>431</fpage>–<lpage>434</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21794866</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>B</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Radi</surname><given-names>R</given-names></name></person-group>
<article-title>Peroxynitrite reactivity with amino acids and proteins</article-title>. <source/>Amino Acids
<volume>25</volume>: <fpage>295</fpage>–<lpage>311</lpage>, <year>2003</year><pub-id pub-id-type="pmid">14661092</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>BN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cathcart</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schwiers</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hochstein</surname><given-names>P</given-names></name></person-group>
<article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>78</volume>: <fpage>6858</fpage>–<lpage>6862</lpage>, <year>1981</year><pub-id pub-id-type="pmid">6947260</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Regueira</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bruhn</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Perez</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Strobel</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dougnac</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marshall</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Leighton</surname><given-names>F</given-names></name></person-group>
<article-title>Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock</article-title>. <source/>Mediators Inflamm
<volume>2008</volume>: <fpage>168652</fpage>–<lpage>168658</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18566692</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkuri</surname><given-names>KR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>
<article-title>N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency</article-title>. <source/>Curr Opin Pharmacol
<volume>7</volume>: <fpage>355</fpage>–<lpage>359</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17602868</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma</article-title>. <source/>J Biol Chem
<volume>268</volume>: <fpage>4161</fpage>–<lpage>4169</lpage>, <year>1993</year><pub-id pub-id-type="pmid">8440704</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>AF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dragovich</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tate</surname><given-names>WR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>RK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roe</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hsu</surname><given-names>C-H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>DL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Powis</surname><given-names>G</given-names></name></person-group>
<article-title>The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma</article-title>. <source/>J Lab Clin Med
<volume>147</volume>: <fpage>83</fpage>–<lpage>90</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16459166</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>JR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Metcalf</surname><given-names>PA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Newman</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Rietz</surname><given-names>P</given-names></name></person-group>
<article-title>Use of protein-based standards in automated colorimetric determinations of fructosamine in serum</article-title>. <source/>Clin Chem
<volume>31</volume>: <fpage>1550</fpage>–<lpage>1554</lpage>, <year>1985</year><pub-id pub-id-type="pmid">4028402</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barregard</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Møller</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mistry</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Koppen</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rossner</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sram</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nataf</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andreoli</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Manini</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marczylo</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lam</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Evans</surname><given-names>MD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kasai</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawai</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>Y-S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sakai</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Teichert</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Farmer</surname><given-names>PB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rozalski</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gackowski</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siomek</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saez</surname><given-names>GT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cerda</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Broberg</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lindh</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hossain</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haghdoost</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hu</surname><given-names>C-W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chao</surname><given-names>M-R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wu</surname><given-names>K-Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Orhan</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Senduran</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Santella</surname><given-names>RM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cortez</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yeh</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olinski</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loft</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Cooke</surname><given-names>MS</given-names></name></person-group>
<article-title>Human and methodological sources of variability in the measurement of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine</article-title>. <source/>Antioxid Redox Signal
<volume>18</volume>: <fpage>2377</fpage>–<lpage>2391</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23198723</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartesaghi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ferrer-Sueta</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Peluffo</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Valez</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kalyanaraman</surname><given-names>B</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Radi</surname><given-names>R</given-names></name></person-group>
<article-title>Protein tyrosine nitration in hydrophilic and hydrophobic environments</article-title>. <source/>Amino Acids
<volume>32</volume>: <fpage>501</fpage>–<lpage>515</lpage>, <year>2006</year><pub-id pub-id-type="pmid">17077966</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battelli</surname><given-names>MG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bolognesi</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Polito</surname><given-names>L</given-names></name></person-group>
<article-title>Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme</article-title>. <source/>Biochim Biophys Acta
<volume>1842</volume>: <fpage>1502</fpage>–<lpage>1517</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24882753</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>SB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maghzal</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hampton</surname><given-names>MB</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group>
<article-title>Neutrophil-mediated oxidation of erythrocyte peroxiredoxin 2 as a potential marker of oxidative stress in inflammation</article-title>. <source/>FASEB J
<volume>27</volume>: <fpage>3315</fpage>–<lpage>3322</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23603832</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bäck</surname><given-names>M</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group>
<article-title>Anti-inflammatory therapies for atherosclerosis</article-title>. <source/>Nat Rev Cardiol
<volume>12</volume>: <fpage>199</fpage>–<lpage>211</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25666404</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergt</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Byun</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McDonald</surname><given-names>TO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anantharamaiah</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chait</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brunzell</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Geary</surname><given-names>RL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oram</surname><given-names>JF</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>
<article-title>The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>101</volume>: <fpage>13032</fpage>–<lpage>13037</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15326314</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowry</surname><given-names>VW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stanley</surname><given-names>KK</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group>
<article-title>High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>89</volume>: <fpage>10316</fpage>–<lpage>10320</lpage>, <year>1992</year><pub-id pub-id-type="pmid">1332045</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brame</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boutaud</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oates</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roden</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Modification of proteins by isoketal-containing oxidized phospholipids</article-title>. <source/>J Biol Chem
<volume>279</volume>: <fpage>13447</fpage>–<lpage>13451</lpage>, <year>2004</year><pub-id pub-id-type="pmid">14715668</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brame</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts</article-title>. <source/>J Biol Chem
<volume>274</volume>: <fpage>13139</fpage>–<lpage>13146</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10224068</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breusing</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grune</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andrisic</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Atalay</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bartosz</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Biasi</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Borovic</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bravo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casals</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casillas</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dinischiotu</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Drzewinska</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faber</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fauzi</surname><given-names>NM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gajewska</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gambini</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gradinaru</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kokkola</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lojek</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luczaj</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Margina</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mascia</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mateos</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinitzer</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mitjavila</surname><given-names>MT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mrakovcic</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Munteanu</surname><given-names>MC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Podborska</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poli</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sicinska</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Skrzydlewska</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vina</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wiswedel</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zelzer</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Spickett</surname><given-names>CM</given-names></name></person-group>
<article-title>An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples</article-title>. <source/>Free Radic Res
<volume>44</volume>: <fpage>1203</fpage>–<lpage>1215</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20836662</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brix</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Höllerl</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kopp</surname><given-names>H-P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>GH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group>
<article-title>The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity</article-title>. <source/>Int J Obes (Lond)
<volume>36</volume>: <fpage>1412</fpage>–<lpage>1417</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22828946</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>JWC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lyons</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klein</surname><given-names>RL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yim</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lopes-Virella</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carter</surname><given-names>RE</given-names></name></person-group>, <collab>(DCCT/EDIC) Research Group</collab>, <person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>SR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Baynes</surname><given-names>JW</given-names></name></person-group>
<article-title>Increased methionine sulfoxide content of apoA-I in type 1 diabetes</article-title>. <source/>J Lipid Res
<volume>49</volume>: <fpage>847</fpage>–<lpage>855</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18202432</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siersma</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Petersen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andersen</surname><given-names>JT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jimenez-Solem</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hansen</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>JE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bonnema</surname><given-names>SJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de Fine Olivarius</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Friis</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Urinary markers of nucleic acid oxidation and cancer in type 2 diabetes</article-title>. <source/>Redox Biol
<volume>4C</volume>: <fpage>34</fpage>–<lpage>39</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25498965</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siersma</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Petersen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andersen</surname><given-names>JT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jimenez-Solem</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stovgaard</surname><given-names>ES</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hansen</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>JE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bonnema</surname><given-names>SJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olivarius Nde</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients</article-title>. <source/>Diabetes Care
<volume>34</volume>: <fpage>2594</fpage>–<lpage>2596</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21994431</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buss</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chan</surname><given-names>TP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sluis</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Domigan</surname><given-names>NM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group>
<article-title>Protein carbonyl measurement by a sensitive ELISA method</article-title>. <source/>Free Radic Biol Med
<volume>23</volume>: <fpage>361</fpage>–<lpage>366</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9214571</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morris</surname><given-names>AD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belch</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hill</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group>
<article-title>Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension</article-title>. <source/>Hypertension
<volume>35</volume>: <fpage>746</fpage>–<lpage>751</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10720589</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabretta</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Küpfer</surname><given-names>PA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Leumann</surname><given-names>CJ</given-names></name></person-group>
<article-title>The effect of RNA base lesions on mRNA translation</article-title>. <source/>Nucleic Acids Res
<volume>43</volume>: <fpage>4713</fpage>–<lpage>4720</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25897124</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carp</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoidal</surname><given-names>JR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Janoff</surname><given-names>A</given-names></name></person-group>
<article-title>Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>79</volume>: <fpage>2041</fpage>–<lpage>2045</lpage>, <year>1982</year><pub-id pub-id-type="pmid">6979049</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Piconi</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ihnat</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Testa</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bonfigli</surname><given-names>AR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group>
<article-title>Glucose “peak” and glucose “spike”: impact on endothelial function and oxidative stress</article-title>. <source/>Diabetes Res Clin Pract
<volume>82</volume>: <fpage>262</fpage>–<lpage>267</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18950890</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Piconi</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group>
<article-title>Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes</article-title>. <source/>Diabetes Care
<volume>30</volume>: <fpage>649</fpage>–<lpage>654</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17327335</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Checconi</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Salzano</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bowler</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mullen</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mengozzi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hanschmann</surname><given-names>E-M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lillig</surname><given-names>CH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sgarbanti</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Panella</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nencioni</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Palamara</surname><given-names>AT</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Redox proteomics of the inflammatory secretome identifies a common set of redoxins and other glutathionylated proteins released in inflammation, influenza virus infection and oxidative stress</article-title>. <source/>PLoS One
<volume>10</volume>: <fpage>e0127086</fpage>, <year>2015</year><pub-id pub-id-type="pmid">25985305</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H-JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lin</surname><given-names>W-P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chiu</surname><given-names>S-D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Fan</surname><given-names>C-H</given-names></name></person-group>
<article-title>Multistage mass spectrometric analysis of human hemoglobin glutathionylation: correlation with cigarette smoking</article-title>. <source/>Chem Res Toxicol
<volume>27</volume>: <fpage>864</fpage>–<lpage>872</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24641270</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>D-K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Perier</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tieu</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Teismann</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wu</surname><given-names>D-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jackson-Lewis</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vila</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vonsattel</surname><given-names>J-P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Przedborski</surname><given-names>S</given-names></name></person-group>
<article-title>Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice</article-title>. <source/>J Neurosci
<volume>25</volume>: <fpage>6594</fpage>–<lpage>6600</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16014720</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalle-Donne</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rossi</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Colombo</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Giustarini</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Milzani</surname><given-names>A</given-names></name></person-group>
<article-title>Biomarkers of oxidative damage in human disease</article-title>. <source/>Clin Chem
<volume>52</volume>: <fpage>601</fpage>–<lpage>623</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16484333</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalle-Donne</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rossi</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Giustarini</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Milzani</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Colombo</surname><given-names>R</given-names></name></person-group>
<article-title>Protein carbonyl groups as biomarkers of oxidative stress</article-title>. <source/>Clin Chim Acta
<volume>329</volume>: <fpage>23</fpage>–<lpage>38</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12589963</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugherty</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dunn</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rateri</surname><given-names>DL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>
<article-title>Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions</article-title>. <source/>J Clin Invest
<volume>94</volume>: <fpage>437</fpage>–<lpage>444</lpage>, <year>1994</year><pub-id pub-id-type="pmid">8040285</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Montine</surname><given-names>KS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bernoud-Hubac</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boutaud</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Montine</surname><given-names>TJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function</article-title>. <source/>FASEB J
<volume>16</volume>: <fpage>715</fpage>–<lpage>717</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11978738</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway</article-title>. <source/>Chem Phys Lipids
<volume>128</volume>: <fpage>85</fpage>–<lpage>99</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15037155</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bodine</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matafonova</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pantazides</surname><given-names>BG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bernoud-Hubac</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harrison</surname><given-names>FE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olson</surname><given-names>SJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Montine</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Treatment with a γ-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice</article-title>. <source/>J Alzheimers Dis
<volume>27</volume>: <fpage>49</fpage>–<lpage>59</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21709376</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>F2-isoprostanes as an indicator and risk factor for coronary heart disease</article-title>. <source/>Free Radic Biol Med
<volume>50</volume>: <fpage>559</fpage>–<lpage>566</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21126576</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>RT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fu</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name></person-group>
<article-title>Biochemistry and pathology of radical-mediated protein oxidation</article-title>. <source/>Biochem J
<volume>324</volume> (<issue>Pt 1</issue>): <fpage>1</fpage>–<lpage>18</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9164834</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>TP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Alderson</surname><given-names>NL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Arrington</surname><given-names>DD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beattie</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Basgen</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steffes</surname><given-names>MW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>SR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Baynes</surname><given-names>JW</given-names></name></person-group>
<article-title>Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat</article-title>. <source/>Kidney Int
<volume>61</volume>: <fpage>939</fpage>–<lpage>950</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11849448</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNicola</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karreth</surname><given-names>FA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Humpton</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gopinathan</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wei</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Frese</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mangal</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yu</surname><given-names>KH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yeo</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>ES</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scrimieri</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Winter</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hruban</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Iacobuzio-Donahue</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kern</surname><given-names>SE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blair</surname><given-names>IA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group>
<article-title>Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis</article-title>. <source/>Nature
<volume>475</volume>: <fpage>106</fpage>–<lpage>109</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21734707</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Giuseppe</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Di Simplicio</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Capecchi</surname><given-names>PL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Pasini</surname><given-names>FL</given-names></name></person-group>
<article-title>Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia</article-title>. <source/>J Lab Clin Med
<volume>142</volume>: <fpage>21</fpage>–<lpage>28</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12878982</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dildar</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sinem</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gökhan</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Orhan</surname><given-names>Y</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Filiz</surname><given-names>M</given-names></name></person-group>
<article-title>Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia</article-title>. <source/>Alzheimer Dis Assoc Disord
<volume>24</volume>: <fpage>194</fpage>–<lpage>197</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20505437</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MW</given-names></name></person-group>
<article-title>A review of approaches to the analysis of 3-nitrotyrosine</article-title>. <source/>Amino Acids
<volume>25</volume>: <fpage>351</fpage>–<lpage>361</lpage>, <year>2003</year><pub-id pub-id-type="pmid">14661096</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eck</surname><given-names>HP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gmünder</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Petzoldt</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daniel</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Dröge</surname><given-names>W</given-names></name></person-group>
<article-title>Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients</article-title>. <source/>Biol Chem Hoppe Seyler
<volume>370</volume>: <fpage>101</fpage>–<lpage>108</lpage>, <year>1989</year><pub-id pub-id-type="pmid">2784973</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><collab>EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)</collab>. <article-title>Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health</article-title>. <source/>EFSA J
<volume>9</volume>: <fpage>2474</fpage>–<lpage>2486</lpage>, <year>2011</year></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enroth</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eger</surname><given-names>BT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nishino</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Pai</surname><given-names>EF</given-names></name></person-group>
<article-title>Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>97</volume>: <fpage>10723</fpage>–<lpage>10728</lpage>, <year>2000</year><pub-id pub-id-type="pmid">11005854</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esterbauer</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schaur</surname><given-names>RJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Zollner</surname><given-names>H</given-names></name></person-group>
<article-title>Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes</article-title>. <source/>Free Radic Biol Med
<volume>11</volume>: <fpage>81</fpage>–<lpage>128</lpage>, <year>1991</year><pub-id pub-id-type="pmid">1937131</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>DB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Van Eyk</surname><given-names>JE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marbán</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>O'Rourke</surname><given-names>B</given-names></name></person-group>
<article-title>Redox signaling and protein phosphorylation in mitochondria: progress and prospects</article-title>. <source/>J Bioenerg Biomembr
<volume>41</volume>: <fpage>159</fpage>–<lpage>168</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19440831</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Horkko</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Dennis</surname><given-names>EA</given-names></name></person-group>
<article-title>Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation</article-title>. <source/>J Biol Chem
<volume>277</volume>: <fpage>7010</fpage>–<lpage>7020</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11744722</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friess</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Waldner</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wahl</surname><given-names>HG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haring</surname><given-names>HU</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Voelter</surname><given-names>W</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schleicher</surname><given-names>E</given-names></name></person-group>
<article-title>Liquid chromatography-based determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects</article-title>. <source/>J Chromatogr B Analyt Technol Biomed Life Sci
<volume>794</volume>: <fpage>273</fpage>–<lpage>280</lpage>, <year>2003</year></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frijhoff</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dagnell</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ostman</surname><given-names>A</given-names></name></person-group>
<article-title>Regulation of protein tyrosine phosphatase oxidation in cell adhesion and migration</article-title>. <source/>Antioxid Redox Signal
<volume>20</volume>: <fpage>1994</fpage>–<lpage>2010</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24111825</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neri</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cesario</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Adams</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Domenici</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dalla Bernardina</surname><given-names>B</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bonassi</surname><given-names>S</given-names></name></person-group>
<article-title>Oxidative stress-related biomarkers in autism: systematic review and meta-analyses</article-title>. <source/>Free Radic Biol Med
<volume>52</volume>: <fpage>2128</fpage>–<lpage>2141</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22542447</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>MX</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Requena</surname><given-names>JR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lyons</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baynes</surname><given-names>JW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>SR</given-names></name></person-group>
<article-title>The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions</article-title>. <source/>J Biol Chem
<volume>271</volume>: <fpage>9982</fpage>–<lpage>9986</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8626637</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ong</surname><given-names>B-H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kupershmidt</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fessel</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anderson</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boyden</surname><given-names>PA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>PC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Balser</surname><given-names>JR</given-names></name></person-group>
<article-title>Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels</article-title>. <source/>Circ Res
<volume>97</volume>: <fpage>1262</fpage>–<lpage>1269</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16284182</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Teichmann</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grossmann</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Aktas</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steigerwald</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Walter</surname><given-names>U</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schinzel</surname><given-names>R</given-names></name></person-group>
<article-title>Monitoring of clopidogrel action: comparison of methods</article-title>. <source/>Clin Chem
<volume>51</volume>: <fpage>957</fpage>–<lpage>965</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15817818</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Protein glutathionylation in health and disease</article-title>. <source/>Biochim Biophys Acta
<volume>1830</volume>: <fpage>3165</fpage>–<lpage>3172</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23416063</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Spreafico</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Salmona</surname><given-names>M</given-names></name></person-group>
<article-title>Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers</article-title>. <source/>Biochem Biophys Res Commun
<volume>119</volume>: <fpage>144</fpage>–<lpage>149</lpage>, <year>1984</year><pub-id pub-id-type="pmid">6584105</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giasson</surname><given-names>BI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Duda</surname><given-names>JE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murray</surname><given-names>IV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Souza</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hurtig</surname><given-names>HI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ischiropoulos</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lee</surname><given-names>VM</given-names></name></person-group>
<article-title>Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions</article-title>. <source/>Science
<volume>290</volume>: <fpage>985</fpage>–<lpage>989</lpage>, <year>2000</year><pub-id pub-id-type="pmid">11062131</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siems</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mazurek</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gross</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Voss</surname><given-names>P</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Grune</surname><given-names>T</given-names></name></person-group>
<article-title>Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes</article-title>. <source/>Free Radic Res
<volume>40</volume>: <fpage>495</fpage>–<lpage>505</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16551576</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greilberger</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Koidl</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Greilberger</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lamprecht</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schroecksnadel</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leblhuber</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Oettl</surname><given-names>K</given-names></name></person-group>
<article-title>Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease</article-title>. <source/>Free Radic Res
<volume>42</volume>: <fpage>633</fpage>–<lpage>638</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18654878</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guéraud</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taché</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steghens</surname><given-names>J-P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Milkovic</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Borovic-Sunjic</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gaultier</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Naud</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Héliès-Toussaint</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pierre</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Priymenko</surname><given-names>N</given-names></name></person-group>
<article-title>Dietary polyunsaturated fatty acids and heme iron induce oxidative stress biomarkers and a cancer promoting environment in the colon of rats</article-title>. <source/>Free Radic Biol Med
<volume>83</volume>: <fpage>192</fpage>–<lpage>200</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25744414</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>
<article-title>A liquid chromatography-tandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines</article-title>. <source/>Anal Biochem
<volume>405</volume>: <fpage>236</fpage>–<lpage>245</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20599652</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cox</surname><given-names>BE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Epand</surname><given-names>RF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Epand</surname><given-names>RM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>
<article-title>Phosphatidylethanolamines modified by γ-ketoaldehyde (γKA) induce endoplasmic reticulum stress and endothelial activation</article-title>. <source/>J Biol Chem
<volume>286</volume>: <fpage>18170</fpage>–<lpage>18180</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21454544</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haehling von</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bode-Böger</surname><given-names>SM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Martens-Lobenhoffer</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rauchhaus</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schefold</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Genth-Zotz</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karhausen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cicoira</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anker</surname><given-names>SD</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Doehner</surname><given-names>W</given-names></name></person-group>
<article-title>Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol</article-title>. <source/>Clin Pharmacol Ther
<volume>88</volume>: <fpage>506</fpage>–<lpage>512</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20827268</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thimmulappa</surname><given-names>RK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kong</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yarmus</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feller-Kopman</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wise</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Biswal</surname><given-names>S</given-names></name></person-group>
<article-title>Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model</article-title>. <source/>Sci Transl Med
<volume>3</volume>: <fpage>78ra32</fpage>, <year>2011</year></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>McMahon</surname><given-names>M</given-names></name></person-group>
<article-title>NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer</article-title>. <source/>Trends Biochem Sci
<volume>34</volume>: <fpage>176</fpage>–<lpage>188</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19321346</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="other">This reference has been deleted.</mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>PT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Evans</surname><given-names>MD</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Cooke</surname><given-names>MS</given-names></name></person-group>
<article-title>Salvage of oxidized guanine derivatives in the (2′-deoxy)ribonucleotide pool as source of mutations in DNA</article-title>. <source/>Mutat Res
<volume>703</volume>: <fpage>11</fpage>–<lpage>17</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20833264</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herce-Pagliai</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kotecha</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Shuker</surname><given-names>DE</given-names></name></person-group>
<article-title>Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review</article-title>. <source/>Nitric Oxide
<volume>2</volume>: <fpage>324</fpage>–<lpage>336</lpage>, <year>1998</year><pub-id pub-id-type="pmid">10100488</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parks</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sahaf</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Perez</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roederer</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>
<article-title>The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford</article-title>. <source/>Clin Chem
<volume>48</volume>: <fpage>1819</fpage>–<lpage>1827</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12324512</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holvoet</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Donck</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Landeloos</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luijtens</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Arnout</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lesaffre</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vanrenterghem</surname><given-names>Y</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Collen</surname><given-names>D</given-names></name></person-group>
<article-title>Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure</article-title>. <source/>Thromb Haemost
<volume>76</volume>: <fpage>663</fpage>–<lpage>669</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8950769</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hool</surname><given-names>LC</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Corry</surname><given-names>B</given-names></name></person-group>
<article-title>Redox control of calcium channels: from mechanisms to therapeutic opportunities</article-title>. <source/>Antioxid Redox Signal
<volume>9</volume>: <fpage>409</fpage>–<lpage>435</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17280484</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ma</surname><given-names>S-R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>W-M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>He</surname><given-names>K-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z-J</given-names></name></person-group>
<article-title>Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma</article-title>. <source/>PLoS One
<volume>8</volume>: <fpage>e83479</fpage>, <year>2013</year><pub-id pub-id-type="pmid">24386210</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sinskey</surname><given-names>AJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group>
<article-title>Oxidized redox state of glutathione in the endoplasmic reticulum</article-title>. <source/>Science
<volume>257</volume>: <fpage>1496</fpage>–<lpage>1502</lpage>, <year>1992</year><pub-id pub-id-type="pmid">1523409</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarra-Alvarado</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Galle</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Melichar</surname><given-names>VO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mameghani</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HHHW</given-names></name></person-group>
<article-title>Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling</article-title>. <source/>Mol Pharmacol
<volume>61</volume>: <fpage>312</fpage>–<lpage>319</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11809855</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Il'yasova</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ivanova</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wagenknecht</surname><given-names>LE</given-names></name></person-group>
<article-title>Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane</article-title>. <source/>Ann Epidemiol
<volume>14</volume>: <fpage>793</fpage>–<lpage>797</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15519902</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mitsuishi</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sakurada</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Endo</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Uruno</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sasano</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Satoh</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kubo</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Motohashi</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<article-title>Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma</article-title>. <source/>Cancer Sci
<volume>103</volume>: <fpage>760</fpage>–<lpage>766</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22320446</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Warabi</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yanagawa</surname><given-names>T</given-names></name></person-group>
<article-title>Novel roles of peroxiredoxins in inflammation, cancer and innate immunity</article-title>. <source/>J Clin Biochem Nutr
<volume>50</volume>: <fpage>91</fpage>–<lpage>105</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22448089</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itabe</surname><given-names>H</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Ueda</surname><given-names>M</given-names></name></person-group>
<article-title>Measurement of plasma oxidized low-density lipoprotein and its clinical implications</article-title>. <source/>J Atheroscler Thromb
<volume>14</volume>: <fpage>1</fpage>–<lpage>11</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17332686</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itabe</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawai</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Imanaka</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Takano</surname><given-names>T</given-names></name></person-group>
<article-title>Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein</article-title>. <source/>J Biol Chem
<volume>271</volume>: <fpage>33208</fpage>–<lpage>33217</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8969177</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen-Heininger</surname><given-names>YMW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mossman</surname><given-names>BT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heintz</surname><given-names>NH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forman</surname><given-names>HJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kalyanaraman</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Finkel</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SG</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>van der Vliet</surname><given-names>A</given-names></name></person-group>
<article-title>Redox-based regulation of signal transduction: principles, pitfalls, and promises</article-title>. <source/>Free Radic Biol Med
<volume>45</volume>: <fpage>1</fpage>–<lpage>17</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18423411</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jiang</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name></person-group>
<article-title>Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival</article-title>. <source/>Int J Clin Exp Pathol
<volume>7</volume>: <fpage>1124</fpage>–<lpage>1131</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24695690</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Travis</surname><given-names>J</given-names></name></person-group>
<article-title>The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center</article-title>. <source/>J Biol Chem
<volume>254</volume>: <fpage>4022</fpage>–<lpage>4026</lpage>, <year>1979</year><pub-id pub-id-type="pmid">312289</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carlson</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mody</surname><given-names>VC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lynn</surname><given-names>MJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>P</given-names></name></person-group>
<article-title>Redox state of glutathione in human plasma</article-title>. <source/>Free Radic Biol Med
<volume>28</volume>: <fpage>625</fpage>–<lpage>635</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10719244</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DP</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Go</surname><given-names>Y-M</given-names></name></person-group>
<article-title>Mapping the cysteine proteome: analysis of redox-sensing thiols</article-title>. <source/>Curr Opin Chem Biol
<volume>15</volume>: <fpage>103</fpage>–<lpage>112</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21216657</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fink-Jensen</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knorr</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Greisen Soendergaard</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jepsen</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lykkesfeldt</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Balslev Jorgensen</surname><given-names>M</given-names></name></person-group>
<article-title>Increased systemic oxidatively generated DNA and RNA damage in schizophrenia</article-title>. <source/>Psychiatry Res
<volume>209</volume>: <fpage>417</fpage>–<lpage>423</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23465294</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadiiska</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gladen</surname><given-names>BC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baird</surname><given-names>DD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Germolec</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Graham</surname><given-names>LB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parker</surname><given-names>CE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nyska</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wachsman</surname><given-names>JT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ames</surname><given-names>BN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Basu</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brot</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>GA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Floyd</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>George</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hatch</surname><given-names>GE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hensley</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lawson</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marnett</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murray</surname><given-names>DM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Plastaras</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rokach</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shigenaga</surname><given-names>MK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sohal</surname><given-names>RS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tice</surname><given-names>RR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Van Thiel</surname><given-names>DH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wellner</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Walter</surname><given-names>PB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tomer</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mason</surname><given-names>RP</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name></person-group>
<article-title>Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?</article-title>
<source/>Free Radic Biol Med
<volume>38</volume>: <fpage>698</fpage>–<lpage>710</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15721980</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplowitz</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fernández-Checa</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kannan</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Garcia-Ruiz</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ookhtens</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yi</surname><given-names>JR</given-names></name></person-group>
<article-title>GSH transporters: molecular characterization and role in GSH homeostasis</article-title>. <source/>Biol Chem Hoppe Seyler
<volume>377</volume>: <fpage>267</fpage>–<lpage>273</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8828817</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Halmes</surname><given-names>NC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hinson</surname><given-names>JA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Pumford</surname><given-names>NR</given-names></name></person-group>
<article-title>Immunochemical detection of oxidized proteins</article-title>. <source/>Chem Res Toxicol
<volume>6</volume>: <fpage>430</fpage>–<lpage>433</lpage>, <year>1993</year><pub-id pub-id-type="pmid">8374038</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettle</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Albrett</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chapman</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dickerhof</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forbes</surname><given-names>LV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Khalilova</surname><given-names>I</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Turner</surname><given-names>R</given-names></name></person-group>
<article-title>Measuring chlorine bleach in biology and medicine</article-title>. <source/>Biochim Biophys Acta
<volume>1840</volume>: <fpage>781</fpage>–<lpage>793</lpage>, <year>2014</year><pub-id pub-id-type="pmid">23872351</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettle</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chan</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Osberg</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Senthilmohan</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chapman</surname><given-names>ALP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mocatta</surname><given-names>TJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wagener</surname><given-names>JS</given-names></name></person-group>
<article-title>Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis</article-title>. <source/>Am J Respir Crit Care Med
<volume>170</volume>: <fpage>1317</fpage>–<lpage>1323</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15466253</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brennand</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bradley</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bruckdorfer</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>M</given-names></name></person-group>
<article-title>3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method</article-title>. <source/>Biochem J
<volume>332</volume> (<issue>Pt 3</issue>): <fpage>807</fpage>–<lpage>808</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9622476</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirabo</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fontana</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de Faria</surname><given-names>APC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loperena</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Galindo</surname><given-names>CL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bikineyeva</surname><given-names>AT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saleh</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Trott</surname><given-names>DW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Itani</surname><given-names>HA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vinh</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amarnath</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>KE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shen</surname><given-names>XZ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shyr</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>S-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mernaugh</surname><given-names>RL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Laffer</surname><given-names>CL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Elijovich</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moreno</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Madhur</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group>
<article-title>DC isoketal-modified proteins activate T cells and promote hypertension</article-title>. <source/>J Clin Invest
<volume>124</volume>: <fpage>4642</fpage>–<lpage>4656</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25244096</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ishii</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y-W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tanito</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Horita</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nishinaka</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yodoi</surname><given-names>J</given-names></name></person-group>
<article-title>Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops</article-title>. <source/>J Immunol
<volume>172</volume>: <fpage>442</fpage>–<lpage>448</lpage>, <year>2004</year><pub-id pub-id-type="pmid">14688353</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunert</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Skurk</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Frank</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lang</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hauner</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>T</given-names></name></person-group>
<article-title>Development and application of a stable isotope dilution analysis for the quantitation of advanced glycation end products of creatinine in biofluids of type 2 diabetic patients and healthy volunteers</article-title>. <source/>Anal Chem
<volume>85</volume>: <fpage>2961</fpage>–<lpage>2969</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23379726</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laragione</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gianazza</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tonelli</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bigini</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mennini</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casoni</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Massignan</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bonetto</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Regulation of redox-sensitive exofacial protein thiols in CHO cells</article-title>. <source/>Biol Chem
<volume>387</volume>: <fpage>1371</fpage>–<lpage>1376</lpage>, <year>2006</year><pub-id pub-id-type="pmid">17081109</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiper</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murray-Rust</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McDonald</surname><given-names>N</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Vallance</surname><given-names>P</given-names></name></person-group>
<article-title>S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>99</volume>: <fpage>13527</fpage>–<lpage>13532</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12370443</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiper</surname><given-names>J</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Nandi</surname><given-names>M</given-names></name></person-group>
<article-title>The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis</article-title>. <source/>Nat Rev Drug Discov
<volume>10</volume>: <fpage>277</fpage>–<lpage>291</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21455237</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Garland</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oliver</surname><given-names>CN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Amici</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Climent</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lenz</surname><given-names>AG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ahn</surname><given-names>BW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shaltiel</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Stadtman</surname><given-names>ER</given-names></name></person-group>
<article-title>Determination of carbonyl content in oxidatively modified proteins</article-title>. <source/>Methods Enzymol
<volume>186</volume>: <fpage>464</fpage>–<lpage>478</lpage>, <year>1990</year><pub-id pub-id-type="pmid">1978225</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Laird</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roychowdhury</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nagy</surname><given-names>LE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Crabb</surname><given-names>JW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group>
<article-title>Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts</article-title>. <source/>Free Radic Biol Med
<volume>47</volume>: <fpage>1539</fpage>–<lpage>1552</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19751823</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loft</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olsen</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Møller</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Tjønneland</surname><given-names>A</given-names></name></person-group>
<article-title>Association between 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study</article-title>. <source/>Cancer Epidemiol Biomarkers Prev
<volume>22</volume>: <fpage>1289</fpage>–<lpage>1296</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23658396</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loft</surname><given-names>S</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Markers of oxidative damage to DNA: antioxidants and molecular damage</article-title>. <source/>Methods Enzymol
<volume>300</volume>: <fpage>166</fpage>–<lpage>184</lpage>, <year>1999</year><pub-id pub-id-type="pmid">9919520</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loft</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Svoboda</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawai</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kasai</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sørensen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tjønneland</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vogel</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Møller</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Overvad</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Raaschou-Nielsen</surname><given-names>O</given-names></name></person-group>
<article-title>Association between 8-oxo-7,8-dihydroguanine excretion and risk of lung cancer in a prospective study</article-title>. <source/>Free Radic Biol Med
<volume>52</volume>: <fpage>167</fpage>–<lpage>172</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22044660</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manevich</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hutchens</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Halushka</surname><given-names>PV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tew</surname><given-names>KD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Townsend</surname><given-names>DM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jauch</surname><given-names>EC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Borg</surname><given-names>K</given-names></name></person-group>
<article-title>Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome</article-title>. <source/>Free Radic Biol Med
<volume>72</volume>: <fpage>210</fpage>–<lpage>221</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24726861</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pétrilli</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mayor</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tardivel</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group>
<article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome</article-title>. <source/>Nature
<volume>440</volume>: <fpage>237</fpage>–<lpage>241</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16407889</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCord</surname><given-names>JM</given-names></name></person-group>
<article-title>Oxygen-derived free radicals in postischemic tissue injury</article-title>. <source/>N Engl J Med
<volume>312</volume>: <fpage>159</fpage>–<lpage>163</lpage>, <year>1985</year><pub-id pub-id-type="pmid">2981404</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCord</surname><given-names>JM</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Fridovich</surname><given-names>I</given-names></name></person-group>
<article-title>The reduction of cytochrome c by milk xanthine oxidase</article-title>. <source/>J Biol Chem
<volume>243</volume>: <fpage>5753</fpage>–<lpage>5760</lpage>, <year>1968</year><pub-id pub-id-type="pmid">4972775</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>VO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Behr-Roussel</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zabel</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Uttenthal</surname><given-names>LO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rupin</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Verbeuren</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kumar H S</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HHHW</given-names></name></person-group>
<article-title>Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>101</volume>: <fpage>16671</fpage>–<lpage>16676</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15546990</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mengozzi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ermilov</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Annenkov</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Pearl</surname><given-names>F</given-names></name></person-group>
<article-title>Definition of a family of tissue-protective cytokines using functional cluster analysis: a proof-of-concept study</article-title>. <source/>Front Immunol
<volume>5</volume>: <fpage>115</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24672526</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>111a</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihm</surname><given-names>MJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jing</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bauer</surname><given-names>JA</given-names></name></person-group>
<article-title>Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage</article-title>. <source/>J Cardiovasc Pharmacol
<volume>36</volume>: <fpage>182</fpage>–<lpage>187</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10942159</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>BJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weiss</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lang</surname><given-names>CA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liu</surname><given-names>MC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>C</given-names></name></person-group>
<article-title>Blood glutathione and cysteine changes in cardiovascular disease</article-title>. <source/>J Lab Clin Med
<volume>135</volume>: <fpage>396</fpage>–<lpage>401</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10811054</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dai</surname><given-names>Q</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>The isoprostanes—25 years later</article-title>. <source/>Biochim Biophys Acta
<volume>1851</volume>: <fpage>433</fpage>–<lpage>445</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25449649</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>SC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Musiek</surname><given-names>ES</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>
<article-title>Quantification of F2-isoprostanes as a biomarker of oxidative stress</article-title>. <source/>Nat Protoc
<volume>2</volume>: <fpage>221</fpage>–<lpage>226</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17401357</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hardy</surname><given-names>KD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Isoprostane generation and function</article-title>. <source/>Chem Rev
<volume>111</volume>: <fpage>5973</fpage>–<lpage>5996</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21848345</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shinzato</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Iida</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van Ypersele de Strihou</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Maeda</surname><given-names>K</given-names></name></person-group>
<article-title>Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine</article-title>. <source/>J Am Soc Nephrol
<volume>7</volume>: <fpage>1198</fpage>–<lpage>1206</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8866413</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>K</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>Measurement of lipid peroxidation</article-title>. <source/>Free Radic Res
<volume>28</volume>: <fpage>659</fpage>–<lpage>671</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9736317</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriarty-Craige</surname><given-names>SE</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Jones</surname><given-names>DP</given-names></name></person-group>
<article-title>Extracellular thiols and thiol/disulfide redox in metabolism</article-title>. <source/>Annu Rev Nutr
<volume>24</volume>: <fpage>481</fpage>–<lpage>509</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15189129</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hill</surname><given-names>KE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Burk</surname><given-names>RF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nammour</surname><given-names>TM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Badr</surname><given-names>KF</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>
<article-title>A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>87</volume>: <fpage>9383</fpage>–<lpage>9387</lpage>, <year>1990</year><pub-id pub-id-type="pmid">2123555</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daniel</surname><given-names>VC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Awad</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mirochnitchenko</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Swift</surname><given-names>LL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Burk</surname><given-names>RF</given-names></name></person-group>
<article-title>Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo—effects of oxygen tension and glutathione</article-title>. <source/>Arch Biochem Biophys
<volume>353</volume>: <fpage>160</fpage>–<lpage>171</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9578611</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murri</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luque-Ramírez</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Insenser</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ojeda-Ojeda</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name></person-group>
<article-title>Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis</article-title>. <source/>Hum Reprod Update
<volume>19</volume>: <fpage>268</fpage>–<lpage>288</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23303572</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutlu-Türkoğlu</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ilhan</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oztezcan</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kuru</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Aykaç-Toker</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Uysal</surname><given-names>M</given-names></name></person-group>
<article-title>Age-related increases in plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in elderly subjects</article-title>. <source/>Clin Biochem
<volume>36</volume>: <fpage>397</fpage>–<lpage>400</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12849873</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagra</surname><given-names>RM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Becher</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tourtellotte</surname><given-names>WW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Antel</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gold</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Paladino</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nelson</surname><given-names>JR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>WF</given-names></name></person-group>
<article-title>Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis</article-title>. <source/>J Neuroimmunol
<volume>78</volume>: <fpage>97</fpage>–<lpage>107</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9307233</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagumo</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chuang</surname><given-names>VTG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Setoyama</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yamada</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kubota</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jinnouchi</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anraku</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ishima</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Otagiri</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>T</given-names></name></person-group>
<article-title>Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases</article-title>. <source/>PLoS One
<volume>9</volume>: <fpage>e85216</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24416365</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>SC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yodoi</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Holmgren</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>
<article-title>Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>98</volume>: <fpage>2688</fpage>–<lpage>2693</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11226300</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negre-Salvayre</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Auge</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ayala</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Basaga</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boada</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brenke</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chapple</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cohen</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feher</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grune</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lengyel</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mann</surname><given-names>GE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pamplona</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poli</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Portero-Otin</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Riahi</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Salvayre</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sasson</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Serrano</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shamni</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siems</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siow</surname><given-names>RCM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wiswedel</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>
<article-title>Pathological aspects of lipid peroxidation</article-title>. <source/>Free Radic Res
<volume>44</volume>: <fpage>1125</fpage>–<lpage>1171</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20836660</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dean</surname><given-names>O</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bush</surname><given-names>AI</given-names></name></person-group>
<article-title>Oxidative stress in psychiatric disorders: evidence base and therapeutic implications</article-title>. <source/>Int J Neuropsychopharmacol
<volume>11</volume>: <fpage>851</fpage>–<lpage>876</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18205981</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="other">This reference has been deleted.</mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onodera</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Motohashi</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Takagi</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shibahara</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ishida</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hirakawa</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sasano</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name></person-group>
<article-title>NRF2 immunolocalization in human breast cancer patients as a prognostic factor</article-title>. <source/>Endocr Relat Cancer
<volume>21</volume>: <fpage>241</fpage>–<lpage>252</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24302665</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantke</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Volk</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmutzler</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kox</surname><given-names>WJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sitte</surname><given-names>N</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Grune</surname><given-names>T</given-names></name></person-group>
<article-title>Oxidized proteins as a marker of oxidative stress during coronary heart surgery</article-title>. <source/>Free Radic Biol Med
<volume>27</volume>: <fpage>1080</fpage>–<lpage>1086</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10569640</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen-Lane</surname><given-names>JH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zurier</surname><given-names>RB</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>DA</given-names></name></person-group>
<article-title>Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients</article-title>. <source/>J Leukoc Biol
<volume>81</volume>: <fpage>934</fpage>–<lpage>941</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17210617</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluffo</surname><given-names>G</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Radi</surname><given-names>R</given-names></name></person-group>
<article-title>Biochemistry of protein tyrosine nitration in cardiovascular pathology</article-title>. <source/>Cardiovasc Res
<volume>75</volume>: <fpage>291</fpage>–<lpage>302</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17544386</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nadal</surname><given-names>LL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>PE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>
<article-title>Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid</article-title>. <source/>Biochim Biophys Acta
<volume>1840</volume>: <fpage>801</fpage>–<lpage>808</lpage>, <year>2014</year><pub-id pub-id-type="pmid">23791936</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Prieme</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Loft</surname><given-names>S</given-names></name></person-group>
<article-title>Role of oxidative DNA damage in cancer initiation and promotion</article-title>. <source/>Eur J Cancer Prev
<volume>7</volume>: <fpage>9</fpage>–<lpage>16</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9511847</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Specht</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ellervik</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mandrup-Poulsen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tonnesen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>PE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andersen</surname><given-names>HU</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>
<article-title>RNA modifications by oxidation: a novel disease mechanism?</article-title>
<source/>Free Radic Biol Med
<volume>52</volume>: <fpage>1353</fpage>–<lpage>1361</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22306201</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>135a</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barden</surname><given-names>AE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loke</surname><given-names>WM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Croft</surname><given-names>KD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Puddey</surname><given-names>IB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mori</surname><given-names>TA</given-names></name></person-group>
<article-title>HDL is the major lipoprotein carrier of plasma F2-isoprostanes</article-title>. <source/>J Lipid Res
<volume>50</volume>: <fpage>716</fpage>–<lpage>722</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19050315</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barden</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mori</surname><given-names>TA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Burke</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Croft</surname><given-names>KD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beilin</surname><given-names>LJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Puddey</surname><given-names>IB</given-names></name></person-group>
<article-title>Measurement of urinary F(<xref ref-type="bibr" rid="B2">2</xref>)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry</article-title>. <source/>Anal Biochem
<volume>272</volume>: <fpage>209</fpage>–<lpage>215</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10415090</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>A-Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Si</surname><given-names>J-Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tang</surname><given-names>X-M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z-Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Qi</surname><given-names>Q-D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Chen</surname><given-names>W-B</given-names></name></person-group>
<article-title>Thioredoxin is a novel diagnostic and prognostic marker in patients with ischemic stroke</article-title>. <source/>Free Radic Biol Med
<volume>80</volume>: <fpage>129</fpage>–<lpage>135</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25555670</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radi</surname><given-names>R</given-names></name></person-group>
<article-title>Peroxynitrite, a stealthy biological oxidant</article-title>. <source/>J Biol Chem
<volume>288</volume>: <fpage>26464</fpage>–<lpage>26472</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23861390</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>WF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rhees</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maciejewski</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Paladino</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sieburg</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maki</surname><given-names>RA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name></person-group>
<article-title>Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease</article-title>. <source/>Exp Neurol
<volume>155</volume>: <fpage>31</fpage>–<lpage>41</lpage>, <year>1999</year><pub-id pub-id-type="pmid">9918702</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fessel</surname><given-names>JP</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>
<article-title>The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation</article-title>. <source/>Brain Pathol
<volume>15</volume>: <fpage>143</fpage>–<lpage>148</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15912887</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JD</given-names></name></person-group>
<article-title>Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation</article-title>. <source/>Cell Mol Life Sci
<volume>59</volume>: <fpage>808</fpage>–<lpage>820</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12088281</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojo</surname><given-names>AI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rada</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mendiola</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ortega-Molina</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wojdyla</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rogowska-Wrzesinska</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hardisson</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Serrano</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>A</given-names></name></person-group>
<article-title>The PTEN/NRF2 axis promotes human carcinogenesis</article-title>. <source/>Antioxid Redox Signal
<volume>21</volume>: <fpage>2498</fpage>–<lpage>2514</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24892215</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryberg</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Söderling</surname><given-names>A-S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davidsson</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Caidahl</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Persson</surname><given-names>LI</given-names></name></person-group>
<article-title>Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease</article-title>. <source/>Neurochem Int
<volume>45</volume>: <fpage>57</fpage>–<lpage>62</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15082222</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabuncu</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vural</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Harma</surname><given-names>M</given-names></name></person-group>
<article-title>Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease</article-title>. <source/>Clin Biochem
<volume>34</volume>: <fpage>407</fpage>–<lpage>413</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11522279</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahaf</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heydari</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>
<article-title>The extracellular microenvironment plays a key role in regulating the redox status of cell surface proteins in HIV-infected subjects</article-title>. <source/>Arch Biochem Biophys
<volume>434</volume>: <fpage>26</fpage>–<lpage>32</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15629105</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>R</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Bi</surname><given-names>W</given-names></name></person-group>
<article-title>Isolevuglandin adducts in disease</article-title>. <source/>Antioxid Redox Signal
<volume>22</volume>: <fpage>1703</fpage>–<lpage>1718</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25557218</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group>
<article-title>Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways</article-title>. <source/>Chem Phys Lipids
<volume>134</volume>: <fpage>1</fpage>–<lpage>20</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15752459</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group>
<article-title>Levuglandins and isolevuglandins: stealthy toxins of oxidative injury</article-title>. <source/>Antioxid Redox Signal
<volume>7</volume>: <fpage>185</fpage>–<lpage>201</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15650407</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jirousek</surname><given-names>MR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sharma</surname><given-names>RB</given-names></name></person-group>
<article-title>Prostaglandin endoperoxides 21. Covalent binding of levuglandin E2 with proteins</article-title>. <source/>Prostaglandins
<volume>34</volume>: <fpage>643</fpage>–<lpage>656</lpage>, <year>1987</year><pub-id pub-id-type="pmid">3481092</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>RG</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Miller</surname><given-names>DB</given-names></name></person-group>
<article-title>Levuglandins: isolation, characterization, and total synthesis of new secoprostanoid products from prostaglandin endoperoxides</article-title>. <source/>Adv Prostaglandin Thromboxane Leukot Res
<volume>15</volume>: <fpage>323</fpage>–<lpage>326</lpage>, <year>1985</year><pub-id pub-id-type="pmid">2936114</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzano</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Checconi</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hanschmann</surname><given-names>E-M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lillig</surname><given-names>CH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bowler</surname><given-names>LD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chan</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vaudry</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mengozzi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Coppo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sacre</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Atkuri</surname><given-names>KR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sahaf</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mullen</surname><given-names>L</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>111</volume>: <fpage>12157</fpage>–<lpage>12162</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25097261</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieber</surname><given-names>M</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group>
<article-title>ROS function in redox signaling and oxidative stress</article-title>. <source/>Curr Biol
<volume>24</volume>: <fpage>R453</fpage>–<lpage>R462</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24845678</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Raff</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vornberger</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Freund</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reber</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schramm</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gambaryan</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wanner</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HHHW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Galle</surname><given-names>J</given-names></name></person-group>
<article-title>L-arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats</article-title>. <source/>Kidney Int
<volume>64</volume>: <fpage>216</fpage>–<lpage>225</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12787412</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schramm</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>La</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heidbreder</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hecker</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lopau</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rendl</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reiners</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Winderl</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wanner</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HHHW</given-names></name></person-group>
<article-title>L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation</article-title>. <source/>Kidney Int
<volume>61</volume>: <fpage>1423</fpage>–<lpage>1432</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11918749</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tsilimingas</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rinze</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reiter</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wendt</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oelze</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Woelken-Weckmüller</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Walter</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reichenspurner</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Münzel</surname><given-names>T</given-names></name></person-group>
<article-title>Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment</article-title>. <source/>Circulation
<volume>105</volume>: <fpage>1170</fpage>–<lpage>1175</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11889009</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H</given-names></name></person-group>
<article-title>Glutathione and its role in cellular functions</article-title>. <source/>Free Radic Biol Med
<volume>27</volume>: <fpage>916</fpage>–<lpage>921</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10569624</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H</given-names></name></person-group>
<article-title>Biochemistry of oxidative stress</article-title>. <source/>Angewandte Chemie
<volume>25</volume>: <fpage>1058</fpage>–<lpage>1071</lpage>, <year>1986</year></mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H</given-names></name></person-group>
<article-title>Oxidative stress: a concept in redox biology and medicine</article-title>. <source/>Redox Biol
<volume>4</volume>: <fpage>180</fpage>–<lpage>183</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25588755</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simms</surname><given-names>CL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hudson</surname><given-names>BH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mosior</surname><given-names>JW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rangwala</surname><given-names>AS</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Zaher</surname><given-names>HS</given-names></name></person-group>
<article-title>An active role for the ribosome in determining the fate of oxidized mRNA</article-title>. <source/>Cell Rep
<volume>9</volume>: <fpage>1256</fpage>–<lpage>1264</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25456128</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Choi</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weisse</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daikhin</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yudkoff</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Obin</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ara</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ischiropoulos</surname><given-names>H</given-names></name></person-group>
<article-title>Proteolytic degradation of tyrosine nitrated proteins</article-title>. <source/>Arch Biochem Biophys
<volume>380</volume>: <fpage>360</fpage>–<lpage>366</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10933892</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Peluffo</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Radi</surname><given-names>R</given-names></name></person-group>
<article-title>Protein tyrosine nitration—functional alteration or just a biomarker?</article-title>
<source/>Free Radic Biol Med
<volume>45</volume>: <fpage>357</fpage>–<lpage>366</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18460345</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spickett</surname><given-names>CM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wiswedel</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Siems</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>
<article-title>Advances in methods for the determination of biologically relevant lipid peroxidation products</article-title>. <source/>Free Radic Res
<volume>44</volume>: <fpage>1172</fpage>–<lpage>1202</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20836661</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiteller</surname><given-names>G</given-names></name></person-group>
<article-title>Linoleic acid peroxidation—the dominant lipid peroxidation process in low density lipoprotein—and its relationship to chronic diseases</article-title>. <source/>Chem Phys Lipids
<volume>95</volume>: <fpage>105</fpage>–<lpage>162</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9853364</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadtman</surname><given-names>ER</given-names></name></person-group>
<article-title>Protein modification in aging</article-title>. <source/>J Gerontol
<volume>43</volume>: <fpage>B112</fpage>–<lpage>B120</lpage>, <year>1988</year><pub-id pub-id-type="pmid">3047204</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parthasarathy</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carew</surname><given-names>TE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Khoo</surname><given-names>JC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group>
<article-title>Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity</article-title>. <source/>N Engl J Med
<volume>320</volume>: <fpage>915</fpage>–<lpage>924</lpage>, <year>1989</year><pub-id pub-id-type="pmid">2648148</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Keaney</surname><given-names>JF</given-names></name></person-group>
<article-title>Role of oxidative modifications in atherosclerosis</article-title>. <source/>Physiol Rev
<volume>84</volume>: <fpage>1381</fpage>–<lpage>1478</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15383655</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultana</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poon</surname><given-names>HF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pierce</surname><given-names>WM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Merchant</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klein</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Butterfield</surname><given-names>DA</given-names></name></person-group>
<article-title>Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach</article-title>. <source/>Neurobiol Dis
<volume>22</volume>: <fpage>76</fpage>–<lpage>87</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16378731</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabó-Taylor</surname><given-names>KÉ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eggleton</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Turner</surname><given-names>CAL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faro</surname><given-names>MLL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tarr</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tóth</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Whiteman</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haigh</surname><given-names>RC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Littlechild</surname><given-names>JA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winyard</surname><given-names>PG</given-names></name></person-group>
<article-title>Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes</article-title>. <source/>Int J Biochem Cell Biol
<volume>44</volume>: <fpage>1223</fpage>–<lpage>1231</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22565169</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kushida</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawana</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name></person-group>
<article-title>Direct quantification of pentosidine in urine and serum by HPLC with column switching</article-title>. <source/>Clin Chem
<volume>42</volume>: <fpage>1439</fpage>–<lpage>1444</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8787701</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chock</surname><given-names>PB</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Stadtman</surname><given-names>ER</given-names></name></person-group>
<article-title>Oxidized messenger RNA induces translation errors</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>104</volume>: <fpage>66</fpage>–<lpage>71</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17190801</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teerlink</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Palm</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>CS</given-names></name></person-group>
<article-title>Cellular ADMA: regulation and action</article-title>. <source/>Pharmacol Res
<volume>60</volume>: <fpage>448</fpage>–<lpage>460</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19682580</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thome</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Münch</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Müller</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schinzel</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blum-Degen</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sitzmann</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rösler</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heidland</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Riederer</surname><given-names>P</given-names></name></person-group>
<article-title>Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease</article-title>. <source/>Life Sci
<volume>59</volume>: <fpage>679</fpage>–<lpage>685</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8761018</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thukkani</surname><given-names>AK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McHowat</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hsu</surname><given-names>F-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brennan</surname><given-names>M-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ford</surname><given-names>DA</given-names></name></person-group>
<article-title>Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions</article-title>. <source/>Circulation
<volume>108</volume>: <fpage>3128</fpage>–<lpage>3133</lpage>, <year>2003</year><pub-id pub-id-type="pmid">14638540</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totan</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yağci</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bardak</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ozyurt</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kendir</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sahin</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sahin Tiğ</surname><given-names>U</given-names></name></person-group>
<article-title>Oxidative macromolecular damage in age-related macular degeneration</article-title>. <source/>Curr Eye Res
<volume>34</volume>: <fpage>1089</fpage>–<lpage>1093</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19958129</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trpkovic</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Resanovic</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stanimirovic</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Radak</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mousa</surname><given-names>SA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cenic-Milosevic</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jevremovic</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Isenovic</surname><given-names>ER</given-names></name></person-group>
<article-title>Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases</article-title>. <source/>Crit Rev Clin Lab Sci<volume>52</volume>: <fpage>70</fpage>–<lpage>85</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25537066</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsikas</surname><given-names>D</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MW</given-names></name></person-group>
<article-title>Mass spectrometry and 3-nitrotyrosine: strategies, controversies, and our current perspective</article-title>. <source/>Mass Spectrom Rev
<volume>33</volume>: <fpage>237</fpage>–<lpage>276</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24167057</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimikas</surname><given-names>S</given-names></name></person-group>
<article-title>Measures of oxidative stress</article-title>. <source/>Clin Lab Med
<volume>26</volume>: <fpage>571</fpage>–<lpage>590</lpage>, v–vi, <year>2006</year><pub-id pub-id-type="pmid">16938585</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimikas</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lau</surname><given-names>HK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Han</surname><given-names>K-R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shortal</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>ER</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Segev</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Curtiss</surname><given-names>LK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Strauss</surname><given-names>BH</given-names></name></person-group>
<article-title>Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein</article-title>. <source/>Circulation
<volume>109</volume>: <fpage>3164</fpage>–<lpage>3170</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15184281</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Itakura</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawakishi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hiai</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Toyokuni</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Stadtman</surname><given-names>ER</given-names></name></person-group>
<article-title>Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies</article-title>. <source/>Arch Biochem Biophys
<volume>324</volume>: <fpage>241</fpage>–<lpage>248</lpage>, <year>1995</year><pub-id pub-id-type="pmid">8554315</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vadseth</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Souza</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thomson</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Seagraves</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nagaswami</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scheiner</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Torbet</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vilaire</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bennett</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murciano</surname><given-names>J-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muzykantov</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Penn</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weisel</surname><given-names>JW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ischiropoulos</surname><given-names>H</given-names></name></person-group>
<article-title>Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species</article-title>. <source/>J Biol Chem
<volume>279</volume>: <fpage>8820</fpage>–<lpage>8826</lpage>, <year>2004</year><pub-id pub-id-type="pmid">14681238</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valko</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leibfritz</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moncol</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cronin</surname><given-names>MTD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mazur</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Telser</surname><given-names>J</given-names></name></person-group>
<article-title>Free radicals and antioxidants in normal physiological functions and human disease</article-title>. <source/>Int J Biochem Cell Biol
<volume>39</volume>: <fpage>44</fpage>–<lpage>84</lpage>, <year>2007</year><pub-id pub-id-type="pmid">16978905</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallance</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leone</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Calver</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Collier</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Moncada</surname><given-names>S</given-names></name></person-group>
<article-title>Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis</article-title>. <source/>J Cardiovasc Pharmacol
<volume>20</volume>
<issue>Suppl 12</issue>: <fpage>S60</fpage>–<lpage>S62</lpage>, <year>1992</year><pub-id pub-id-type="pmid">1282988</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vliet</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eiserich</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Cross</surname><given-names>CE</given-names></name></person-group>
<article-title>Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity</article-title>. <source/>J Biol Chem
<volume>272</volume>: <fpage>7617</fpage>–<lpage>7625</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9065416</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vita</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brennan</surname><given-names>M-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gokce</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mann</surname><given-names>SA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Goormastic</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shishehbor</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Penn</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Keaney</surname><given-names>JF</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group>
<article-title>Serum myeloperoxidase levels independently predict endothelial dysfunction in humans</article-title>. <source/>Circulation
<volume>110</volume>: <fpage>1134</fpage>–<lpage>1139</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15326065</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wacker</surname><given-names>BK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Albert</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ford</surname><given-names>BA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ford</surname><given-names>DA</given-names></name></person-group>
<article-title>Strategies for the analysis of chlorinated lipids in biological systems</article-title>. <source/>Free Radic Biol Med
<volume>59</volume>: <fpage>92</fpage>–<lpage>99</lpage>, <year>2013</year><pub-id pub-id-type="pmid">22713364</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waeg</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dimsity</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Esterbauer</surname><given-names>H</given-names></name></person-group>
<article-title>Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins</article-title>. <source/>Free Radic Res
<volume>25</volume>: <fpage>149</fpage>–<lpage>159</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8885333</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakita</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Akagawa</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name></person-group>
<article-title>A method for detection of 4-hydroxy-2-nonenal adducts in proteins</article-title>. <source/>Free Radic Biol Med
<volume>51</volume>: <fpage>1</fpage>–<lpage>4</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21457776</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wayenberg</surname><given-names>J-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ransy</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vermeylen</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Damis</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bottari</surname><given-names>SP</given-names></name></person-group>
<article-title>Nitrated plasma albumin as a marker of nitrative stress and neonatal encephalopathy in perinatal asphyxia</article-title>. <source/>Free Radic Biol Med
<volume>47</volume>: <fpage>975</fpage>–<lpage>982</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19591921</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belling</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Measurement of 8-oxo-2"-deoxyguanosine and 8-oxo-2-"deoxyadenosine in DNA and human urine by high performance liquid chromatography-electrospray tandem mass spectrometry</article-title>. <source/>Free Radic Biol Med
<volume>30</volume>: <fpage>757</fpage>–<lpage>764</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11275475</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belling</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Quantification of 8-oxo-guanine and guanine as the nucleobase, nucleoside and deoxynucleoside forms in human urine by high-performance liquid chromatography-electrospray tandem mass spectrometry</article-title>. <source/>Nucleic Acids Res
<volume>30</volume>: <fpage>E7</fpage>, <year>2002</year><pub-id pub-id-type="pmid">11788733</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weimann</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Broedbaek</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stovgaard</surname><given-names>ES</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>
<article-title>Assays for urinary biomarkers of oxidatively damaged nucleic acids</article-title>. <source/>Free Radic Res
<volume>46</volume>: <fpage>531</fpage>–<lpage>540</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22352957</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192</label>
<mixed-citation publication-type="book"><collab>WHO</collab>. <source/>Biomarkers in Risk assessment: Validity and Validation. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>2001</year></mixed-citation>
</ref>
<ref id="B193">
<label>193</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witko-Sarsat</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nguyen Khoa</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jungers</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Drüeke</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Descamps-Latscha</surname><given-names>B</given-names></name></person-group>
<article-title>Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia</article-title>. <source/>Adv Nephrol Necker Hosp
<volume>28</volume>: <fpage>321</fpage>–<lpage>341</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9889997</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Willett</surname><given-names>WC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rifai</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shai</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Manson</surname><given-names>JE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group>
<article-title>Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?</article-title>
<source/>J Am Coll Cardiol
<volume>48</volume>: <fpage>973</fpage>–<lpage>979</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16949489</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamakura</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taka</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Murayama</surname><given-names>K</given-names></name></person-group>
<article-title>Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine</article-title>. <source/>J Biol Chem
<volume>273</volume>: <fpage>14085</fpage>–<lpage>14089</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9603906</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lin</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name></person-group>
<article-title>The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer</article-title>. <source/>Clin Lung Cancer
<volume>12</volume>: <fpage>166</fpage>–<lpage>171</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21663859</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ingelse</surname><given-names>BA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Smythe</surname><given-names>GA</given-names></name></person-group>
<article-title>Quantification of 3-nitrotyrosine in biological tissues and fluids: generating valid results by eliminating artifactual formation</article-title>. <source/>J Am Soc Mass Spectrom
<volume>11</volume>: <fpage>578</fpage>–<lpage>586</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10833032</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Porter</surname><given-names>NA</given-names></name></person-group>
<article-title>New insights regarding the autoxidation of polyunsaturated fatty acids</article-title>. <source/>Antioxid Redox Signal
<volume>7</volume>: <fpage>170</fpage>–<lpage>184</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15650406</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yodoi</surname><given-names>J</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M</given-names></name></person-group>
<article-title>Discovery of ATL: an odyssey in restrospect</article-title>. <source/>Int J Hematol
<volume>94</volume>: <fpage>423</fpage>–<lpage>428</lpage>, <year>2011</year><pub-id pub-id-type="pmid">22068231</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>
<article-title>4-Hydroxynonenal as a bioactive marker of pathophysiological processes</article-title>. <source/>Mol Aspects Med
<volume>24</volume>: <fpage>281</fpage>–<lpage>291</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12893006</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<title>Abbreviations Used</title>
<def-list>
<def-item>
<term id="G1">3-Cl-Tyr</term>
<def>
<p>3-chlorotyrosine</p>
</def>
</def-item>
<def-item>
<term id="G2">4-HNE</term>
<def>
<p><italic>trans</italic>-4-hydroxy-2-nonenal</p>
</def>
</def-item>
<def-item>
<term id="G3">8oxodG</term>
<def>
<p>7,8-dihydro-8-oxo-2′-deoxyguanosine</p>
</def>
</def-item>
<def-item>
<term id="G4">8oxoGuo</term>
<def>
<p>7,8-dihydro-8-oxo-guanosine</p>
</def>
</def-item>
<def-item>
<term id="G5">AA</term>
<def>
<p>arachidonic acid</p>
</def>
</def-item>
<def-item>
<term id="G6">ACS</term>
<def>
<p>acute coronary syndrome</p>
</def>
</def-item>
<def-item>
<term id="G7">AD</term>
<def>
<p>Alzheimer's disease</p>
</def>
</def-item>
<def-item>
<term id="G8">ADMA</term>
<def>
<p>asymmetric dimethyl L-arginine</p>
</def>
</def-item>
<def-item>
<term id="G9">AGEs</term>
<def>
<p>advanced glycation end products</p>
</def>
</def-item>
<def-item>
<term id="G10">AIDS</term>
<def>
<p>acquired immunodeficiency syndrome</p>
</def>
</def-item>
<def-item>
<term id="G11">AMI</term>
<def>
<p>acute myocardial infarction</p>
</def>
</def-item>
<def-item>
<term id="G12">ASD</term>
<def>
<p>autism spectrum disorders</p>
</def>
</def-item>
<def-item>
<term id="G13">AT1R</term>
<def>
<p>angiotensin receptor 1</p>
</def>
</def-item>
<def-item>
<term id="G14">BMI</term>
<def>
<p>body–mass index</p>
</def>
</def-item>
<def-item>
<term id="G15">CAD</term>
<def>
<p>coronary artery disease</p>
</def>
</def-item>
<def-item>
<term id="G16">CBS</term>
<def>
<p>cardiac biomarker score</p>
</def>
</def-item>
<def-item>
<term id="G17">CPB</term>
<def>
<p>cardiopulmonary bypass</p>
</def>
</def-item>
<def-item>
<term id="G18">cGMP</term>
<def>
<p>cyclic guanosine monophosphate</p>
</def>
</def-item>
<def-item>
<term id="G19">CHD</term>
<def>
<p>coronary heart disease</p>
</def>
</def-item>
<def-item>
<term id="G20">CKD</term>
<def>
<p>chronic kidney disease;</p>
</def>
</def-item>
<def-item>
<term id="G21">CML</term>
<def>
<p>carboxymethyl lysine</p>
</def>
</def-item>
<def-item>
<term id="G22">CO<sub>2</sub></term>
<def>
<p>carbon dioxide</p>
</def>
</def-item>
<def-item>
<term id="G23">CRF</term>
<def>
<p>chronic renal failure</p>
</def>
</def-item>
<def-item>
<term id="G24">CRP</term>
<def>
<p>C-reactive protein</p>
</def>
</def-item>
<def-item>
<term id="G25">CSF</term>
<def>
<p>cerebrospinal fluid</p>
</def>
</def-item>
<def-item>
<term id="G26">CVD</term>
<def>
<p>cardiovascular disease</p>
</def>
</def-item>
<def-item>
<term id="G27">DDAH</term>
<def>
<p><italic>N<sup>G</sup>-N<sup>G</sup></italic>-dimethylarginine dimethylaminohydrolase</p>
</def>
</def-item>
<def-item>
<term id="G28">DNP</term>
<def>
<p>2,4-dinitrophenylhydrazine</p>
</def>
</def-item>
<def-item>
<term id="G29">eNOS</term>
<def>
<p>endothelial NOS</p>
</def>
</def-item>
<def-item>
<term id="G30">FC</term>
<def>
<p>flow cytometry</p>
</def>
</def-item>
<def-item>
<term id="G31">GC</term>
<def>
<p>gas chromatography</p>
</def>
</def-item>
<def-item>
<term id="G32">Grx</term>
<def>
<p>glutaredoxin</p>
</def>
</def-item>
<def-item>
<term id="G33">GSH</term>
<def>
<p>glutathione</p>
</def>
</def-item>
<def-item>
<term id="G34">GSSG</term>
<def>
<p>oxidized glutathione</p>
</def>
</def-item>
<def-item>
<term id="G35">H<sub>2</sub>O<sub>2</sub></term>
<def>
<p>hydrogen peroxide</p>
</def>
</def-item>
<def-item>
<term id="G36">HCC</term>
<def>
<p>hepatocellular carcinoma</p>
</def>
</def-item>
<def-item>
<term id="G37">HDL</term>
<def>
<p>high-density lipoprotein</p>
</def>
</def-item>
<def-item>
<term id="G38">HIV</term>
<def>
<p>human immunodeficiency virus</p>
</def>
</def-item>
<def-item>
<term id="G39">HOCl</term>
<def>
<p>hypochlorous acid</p>
</def>
</def-item>
<def-item>
<term id="G40">HPLC</term>
<def>
<p>high-performance liquid chromatography</p>
</def>
</def-item>
<def-item>
<term id="G41">IHC</term>
<def>
<p>immunohistochemistry</p>
</def>
</def-item>
<def-item>
<term id="G42">IL-6</term>
<def>
<p>interleukin-6</p>
</def>
</def-item>
<def-item>
<term id="G43">IS</term>
<def>
<p>ischemic stroke</p>
</def>
</def-item>
<def-item>
<term id="G44">IsoLG</term>
<def>
<p>isolevuglandins</p>
</def>
</def-item>
<def-item>
<term id="G45">IsoPs</term>
<def>
<p>isoprostanes</p>
</def>
</def-item>
<def-item>
<term id="G46">LC</term>
<def>
<p>liquid chromatography</p>
</def>
</def-item>
<def-item>
<term id="G47">LDL</term>
<def>
<p>low-density lipoprotein</p>
</def>
</def-item>
<def-item>
<term id="G48">MACE</term>
<def>
<p>major adverse cardiac events</p>
</def>
</def-item>
<def-item>
<term id="G49">MCI</term>
<def>
<p>myocardial infarction</p>
</def>
</def-item>
<def-item>
<term id="G50">MDA</term>
<def>
<p>malondialdehyde</p>
</def>
</def-item>
<def-item>
<term id="G51">MI</term>
<def>
<p>myocardial infarct</p>
</def>
</def-item>
<def-item>
<term id="G52">MPO</term>
<def>
<p>myeloperoxidase</p>
</def>
</def-item>
<def-item>
<term id="G53">MS</term>
<def>
<p>mass spectrometry</p>
</def>
</def-item>
<def-item>
<term id="G54">NO</term>
<def>
<p>nitric oxide</p>
</def>
</def-item>
<def-item>
<term id="G55">NOS</term>
<def>
<p>NO synthase</p>
</def>
</def-item>
<def-item>
<term id="G56">NOX</term>
<def>
<p>NADPH oxidase</p>
</def>
</def-item>
<def-item>
<term id="G57">NRF2</term>
<def>
<p>nuclear factor (erythroid-derived 2)-like 2</p>
</def>
</def-item>
<def-item>
<term id="G58">NRP</term>
<def>
<p>nonradical product</p>
</def>
</def-item>
<def-item>
<term id="G59">OA</term>
<def>
<p>osteoarthritis</p>
</def>
</def-item>
<def-item>
<term id="G60">ONOOCO<sub>2</sub></term>
<def>
<p>nitrosoperoxocarbonate</p>
</def>
</def-item>
<def-item>
<term id="G61">oxLDL</term>
<def>
<p>oxidized LDL</p>
</def>
</def-item>
<def-item>
<term id="G62">OxRed</term>
<def>
<p>oxidoreductases</p>
</def>
</def-item>
<def-item>
<term id="G63">PAD</term>
<def>
<p>peripheral artery disease</p>
</def>
</def-item>
<def-item>
<term id="G64">PC</term>
<def>
<p>protein carbonyls</p>
</def>
</def-item>
<def-item>
<term id="G65">PCI</term>
<def>
<p>percutaneous coronary intervention</p>
</def>
</def-item>
<def-item>
<term id="G66">PCOS</term>
<def>
<p>polycystic ovary syndrome</p>
</def>
</def-item>
<def-item>
<term id="G67">PCR</term>
<def>
<p>polymerase chain reaction</p>
</def>
</def-item>
<def-item>
<term id="G68">PDGF</term>
<def>
<p>platelet-derived growth factor</p>
</def>
</def-item>
<def-item>
<term id="G69">PSE</term>
<def>
<p>post-stroke epilepsy</p>
</def>
</def-item>
<def-item>
<term id="G70">P-VASP</term>
<def>
<p>phosphorylated vasodilator-stimulated phosphoprotein</p>
</def>
</def-item>
<def-item>
<term id="G71">Pr-SS-G</term>
<def>
<p>protein mixed disulfide</p>
</def>
</def-item>
<def-item>
<term id="G72">PrCarb</term>
<def>
<p>protein carbonyls</p>
</def>
</def-item>
<def-item>
<term id="G73">Prx</term>
<def>
<p>peroxiredoxin</p>
</def>
</def-item>
<def-item>
<term id="G74">PUFA</term>
<def>
<p>polyunsaturated fatty acids</p>
</def>
</def-item>
<def-item>
<term id="G75">qRT-PCR</term>
<def>
<p>quantitative real time polymerase chain reaction</p>
</def>
</def-item>
<def-item>
<term id="G76">RA</term>
<def>
<p>rheumatoid arthritis</p>
</def>
</def-item>
<def-item>
<term id="G77">RBC</term>
<def>
<p>red blood cell</p>
</def>
</def-item>
<def-item>
<term id="G78">RNS</term>
<def>
<p>reactive nitrogen species</p>
</def>
</def-item>
<def-item>
<term id="G79">ROS</term>
<def>
<p>reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term id="G80">SAF</term>
<def>
<p>skin autofluorescence</p>
</def>
</def-item>
<def-item>
<term id="G81">sGC</term>
<def>
<p>soluble guanylate cyclase</p>
</def>
</def-item>
<def-item>
<term id="G82">SLE</term>
<def>
<p>systemic lupus erythematosus</p>
</def>
</def-item>
<def-item>
<term id="G83">SODs</term>
<def>
<p>superoxide dismutases</p>
</def>
</def-item>
<def-item>
<term id="G84">sRAGE</term>
<def>
<p>secreted receptor for AGE</p>
</def>
</def-item>
<def-item>
<term id="G85">T1D</term>
<def>
<p>type 1 diabetes</p>
</def>
</def-item>
<def-item>
<term id="G86">T2D</term>
<def>
<p>type 2 diabetes</p>
</def>
</def-item>
<def-item>
<term id="G87">TBARS</term>
<def>
<p>thiobarbituric acid reactive substances</p>
</def>
</def-item>
<def-item>
<term id="G88">TNF</term>
<def>
<p>tumor necrosis factor</p>
</def>
</def-item>
<def-item>
<term id="G89">TnT</term>
<def>
<p>troponin T</p>
</def>
</def-item>
<def-item>
<term id="G90">Trx</term>
<def>
<p>thioredoxin</p>
</def>
</def-item>
<def-item>
<term id="G91">Tyr-NO<sub>2</sub></term>
<def>
<p>nitrotyrosine</p>
</def>
</def-item>
<def-item>
<term id="G92">u-eNOS</term>
<def>
<p>uncoupled eNOS</p>
</def>
</def-item>
<def-item>
<term id="G93">UPLC</term>
<def>
<p>ultra performance LC</p>
</def>
</def-item>
<def-item>
<term id="G94">XDH</term>
<def>
<p>xanthine dehydrogenase</p>
</def>
</def-item>
<def-item>
<term id="G95">XO</term>
<def>
<p>xanthine oxidase</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>